51
|
Zhang H, Huang J, Xie J, Huang W, Yang Y, Xu M, Lei J, Chen H. GRELinker: A Graph-Based Generative Model for Molecular Linker Design with Reinforcement and Curriculum Learning. J Chem Inf Model 2024; 64:666-676. [PMID: 38241022 DOI: 10.1021/acs.jcim.3c01700] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/13/2024]
Abstract
Fragment-based drug discovery (FBDD) is widely used in drug design. One useful strategy in FBDD is designing linkers for linking fragments to optimize their molecular properties. In the current study, we present a novel generative fragment linking model, GRELinker, which utilizes a gated-graph neural network combined with reinforcement and curriculum learning to generate molecules with desirable attributes. The model has been shown to be efficient in multiple tasks, including controlling log P, optimizing synthesizability or predicted bioactivity of compounds, and generating molecules with high 3D similarity but low 2D similarity to the lead compound. Specifically, our model outperforms the previously reported reinforcement learning (RL) built-in method DRlinker on these benchmark tasks. Moreover, GRELinker has been successfully used in an actual FBDD case to generate optimized molecules with enhanced affinities by employing the docking score as the scoring function in RL. Besides, the implementation of curriculum learning in our framework enables the generation of structurally complex linkers more efficiently. These results demonstrate the benefits and feasibility of GRELinker in linker design for molecular optimization and drug discovery.
Collapse
Affiliation(s)
- Hao Zhang
- School of Pharmaceutical Science, Sun Yat-sen University, Guangzhou 510006, China
| | - Jinchao Huang
- School of Pharmaceutical Science, Sun Yat-sen University, Guangzhou 510006, China
| | - Junjie Xie
- School of Computer Science and Engineering, Sun Yat-sen University, Guangzhou 510006, China
| | - Weifeng Huang
- School of Pharmaceutical Science, Sun Yat-sen University, Guangzhou 510006, China
| | - Yuedong Yang
- School of Computer Science and Engineering, Sun Yat-sen University, Guangzhou 510006, China
| | - Mingyuan Xu
- Guangzhou National Laboratory, Guangzhou International Bio Island, No. 9 Xin Dao Huan Bei Road, Guangzhou 510005, China
| | - Jinping Lei
- School of Pharmaceutical Science, Sun Yat-sen University, Guangzhou 510006, China
| | - Hongming Chen
- Guangzhou National Laboratory, Guangzhou International Bio Island, No. 9 Xin Dao Huan Bei Road, Guangzhou 510005, China
| |
Collapse
|
52
|
Kyro GW, Morgunov A, Brent RI, Batista VS. ChemSpaceAL: An Efficient Active Learning Methodology Applied to Protein-Specific Molecular Generation. J Chem Inf Model 2024; 64:653-665. [PMID: 38287889 DOI: 10.1021/acs.jcim.3c01456] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2024]
Abstract
The incredible capabilities of generative artificial intelligence models have inevitably led to their application in the domain of drug discovery. Within this domain, the vastness of chemical space motivates the development of more efficient methods for identifying regions with molecules that exhibit desired characteristics. In this work, we present a computationally efficient active learning methodology and demonstrate its applicability to targeted molecular generation. When applied to c-Abl kinase, a protein with FDA-approved small-molecule inhibitors, the model learns to generate molecules similar to the inhibitors without prior knowledge of their existence and even reproduces two of them exactly. We also show that the methodology is effective for a protein without any commercially available small-molecule inhibitors, the HNH domain of the CRISPR-associated protein 9 (Cas9) enzyme. To facilitate implementation and reproducibility, we made all of our software available through the open-source ChemSpaceAL Python package.
Collapse
Affiliation(s)
- Gregory W Kyro
- Department of Chemistry, Yale University, New Haven, Connecticut 06511-8499, United States
| | - Anton Morgunov
- Department of Chemistry, Yale University, New Haven, Connecticut 06511-8499, United States
| | - Rafael I Brent
- Department of Chemistry, Yale University, New Haven, Connecticut 06511-8499, United States
| | - Victor S Batista
- Department of Chemistry, Yale University, New Haven, Connecticut 06511-8499, United States
| |
Collapse
|
53
|
Shen T, Guo J, Han Z, Zhang G, Liu Q, Si X, Wang D, Wu S, Xia J. AutoMolDesigner for Antibiotic Discovery: An AI-Based Open-Source Software for Automated Design of Small-Molecule Antibiotics. J Chem Inf Model 2024; 64:575-583. [PMID: 38265916 DOI: 10.1021/acs.jcim.3c01562] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2024]
Abstract
Discovery of small-molecule antibiotics with novel chemotypes serves as one of the essential strategies to address antibiotic resistance. Although a considerable number of computational tools committed to molecular design have been reported, there is a deficit in holistic and efficient tools specifically developed for small-molecule antibiotic discovery. To address this issue, we report AutoMolDesigner, a computational modeling software dedicated to small-molecule antibiotic design. It is a generalized framework comprising two functional modules, i.e., generative-deep-learning-enabled molecular generation and automated machine-learning-based antibacterial activity/property prediction, wherein individually trained models and curated datasets are out-of-the-box for whole-cell-based antibiotic screening and design. It is open-source, thus allowing for the incorporation of new features for flexible use. Unlike most software programs based on Linux and command lines, this application equipped with a Qt-based graphical user interface can be run on personal computers with multiple operating systems, making it much easier to use for experimental scientists. The software and related materials are freely available at GitHub (https://github.com/taoshen99/AutoMolDesigner) and Zenodo (https://zenodo.org/record/10097899).
Collapse
Affiliation(s)
- Tao Shen
- State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China
| | - Jiale Guo
- State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China
| | - Zunsheng Han
- State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China
| | - Gao Zhang
- State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China
| | - Qingxin Liu
- State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China
- School of Pharmacy, Jiangsu Ocean University, Lianyungang, Jiangsu 222005, China
| | - Xinxin Si
- School of Pharmacy, Jiangsu Ocean University, Lianyungang, Jiangsu 222005, China
| | - Dongmei Wang
- State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China
| | - Song Wu
- State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China
| | - Jie Xia
- State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China
| |
Collapse
|
54
|
Gangwal A, Ansari A, Ahmad I, Azad AK, Kumarasamy V, Subramaniyan V, Wong LS. Generative artificial intelligence in drug discovery: basic framework, recent advances, challenges, and opportunities. Front Pharmacol 2024; 15:1331062. [PMID: 38384298 PMCID: PMC10879372 DOI: 10.3389/fphar.2024.1331062] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2023] [Accepted: 01/17/2024] [Indexed: 02/23/2024] Open
Abstract
There are two main ways to discover or design small drug molecules. The first involves fine-tuning existing molecules or commercially successful drugs through quantitative structure-activity relationships and virtual screening. The second approach involves generating new molecules through de novo drug design or inverse quantitative structure-activity relationship. Both methods aim to get a drug molecule with the best pharmacokinetic and pharmacodynamic profiles. However, bringing a new drug to market is an expensive and time-consuming endeavor, with the average cost being estimated at around $2.5 billion. One of the biggest challenges is screening the vast number of potential drug candidates to find one that is both safe and effective. The development of artificial intelligence in recent years has been phenomenal, ushering in a revolution in many fields. The field of pharmaceutical sciences has also significantly benefited from multiple applications of artificial intelligence, especially drug discovery projects. Artificial intelligence models are finding use in molecular property prediction, molecule generation, virtual screening, synthesis planning, repurposing, among others. Lately, generative artificial intelligence has gained popularity across domains for its ability to generate entirely new data, such as images, sentences, audios, videos, novel chemical molecules, etc. Generative artificial intelligence has also delivered promising results in drug discovery and development. This review article delves into the fundamentals and framework of various generative artificial intelligence models in the context of drug discovery via de novo drug design approach. Various basic and advanced models have been discussed, along with their recent applications. The review also explores recent examples and advances in the generative artificial intelligence approach, as well as the challenges and ongoing efforts to fully harness the potential of generative artificial intelligence in generating novel drug molecules in a faster and more affordable manner. Some clinical-level assets generated form generative artificial intelligence have also been discussed in this review to show the ever-increasing application of artificial intelligence in drug discovery through commercial partnerships.
Collapse
Affiliation(s)
- Amit Gangwal
- Department of Natural Product Chemistry, Shri Vile Parle Kelavani Mandal’s Institute of Pharmacy, Dhule, Maharashtra, India
| | - Azim Ansari
- Computer Aided Drug Design Center Shri Vile Parle Kelavani Mandal’s Institute of Pharmacy, Dhule, Maharashtra, India
| | - Iqrar Ahmad
- Department of Pharmaceutical Chemistry, Prof. Ravindra Nikam College of Pharmacy, Dhule, India
| | - Abul Kalam Azad
- Faculty of Pharmacy, University College of MAIWP International, Batu Caves, Malaysia
| | - Vinoth Kumarasamy
- Department of Parasitology and Medical Entomology, Faculty of Medicine, Universiti Kebangsaan Malaysia, Cheras, Malaysia
| | - Vetriselvan Subramaniyan
- Pharmacology Unit, Jeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia, Selangor, Malaysia
- School of Bioengineering and Biosciences, Lovely Professional University, Phagwara, Punjab, India
| | - Ling Shing Wong
- Faculty of Health and Life Sciences, INTI International University, Nilai, Malaysia
| |
Collapse
|
55
|
Jinsong S, Qifeng J, Xing C, Hao Y, Wang L. Molecular fragmentation as a crucial step in the AI-based drug development pathway. Commun Chem 2024; 7:20. [PMID: 38302655 PMCID: PMC10834946 DOI: 10.1038/s42004-024-01109-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2023] [Accepted: 01/19/2024] [Indexed: 02/03/2024] Open
Abstract
The AI-based small molecule drug discovery has become a significant trend at the intersection of computer science and life sciences. In the pursuit of novel compounds, fragment-based drug discovery has emerged as a novel approach. The Generative Pre-trained Transformers (GPT) model has showcased remarkable prowess across various domains, rooted in its pre-training and representation learning of fundamental linguistic units. Analogous to natural language, molecular encoding, as a form of chemical language, necessitates fragmentation aligned with specific chemical logic for accurate molecular encoding. This review provides a comprehensive overview of the current state of the art in molecular fragmentation. We systematically summarize the approaches and applications of various molecular fragmentation techniques, with special emphasis on the characteristics and scope of applicability of each technique, and discuss their applications. We also provide an outlook on the current development trends of molecular fragmentation techniques, including some potential research directions and challenges.
Collapse
Affiliation(s)
- Shao Jinsong
- Nantong University, School of Information Science and Technology, Nantong, China
| | - Jia Qifeng
- Nantong University, School of Information Science and Technology, Nantong, China
| | - Chen Xing
- Nantong University, School of Information Science and Technology, Nantong, China
| | - Yajie Hao
- Nantong University, School of Information Science and Technology, Nantong, China
| | - Li Wang
- Nantong University, Research Center for Intelligence Information Technology, Nantong, China.
| |
Collapse
|
56
|
Tropsha A, Isayev O, Varnek A, Schneider G, Cherkasov A. Integrating QSAR modelling and deep learning in drug discovery: the emergence of deep QSAR. Nat Rev Drug Discov 2024; 23:141-155. [PMID: 38066301 DOI: 10.1038/s41573-023-00832-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/21/2023] [Indexed: 02/08/2024]
Abstract
Quantitative structure-activity relationship (QSAR) modelling, an approach that was introduced 60 years ago, is widely used in computer-aided drug design. In recent years, progress in artificial intelligence techniques, such as deep learning, the rapid growth of databases of molecules for virtual screening and dramatic improvements in computational power have supported the emergence of a new field of QSAR applications that we term 'deep QSAR'. Marking a decade from the pioneering applications of deep QSAR to tasks involved in small-molecule drug discovery, we herein describe key advances in the field, including deep generative and reinforcement learning approaches in molecular design, deep learning models for synthetic planning and the application of deep QSAR models in structure-based virtual screening. We also reflect on the emergence of quantum computing, which promises to further accelerate deep QSAR applications and the need for open-source and democratized resources to support computer-aided drug design.
Collapse
Affiliation(s)
| | | | | | | | - Artem Cherkasov
- University of British Columbia, Vancouver, BC, Canada.
- Photonic Inc., Coquitlam, BC, Canada.
| |
Collapse
|
57
|
Satalkar V, Degaga GD, Li W, Pang YT, McShan AC, Gumbart JC, Mitchell JC, Torres MP. Generative β-hairpin design using a residue-based physicochemical property landscape. Biophys J 2024:S0006-3495(24)00070-5. [PMID: 38297834 DOI: 10.1016/j.bpj.2024.01.029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2023] [Revised: 12/20/2023] [Accepted: 01/25/2024] [Indexed: 02/02/2024] Open
Abstract
De novo peptide design is a new frontier that has broad application potential in the biological and biomedical fields. Most existing models for de novo peptide design are largely based on sequence homology that can be restricted based on evolutionarily derived protein sequences and lack the physicochemical context essential in protein folding. Generative machine learning for de novo peptide design is a promising way to synthesize theoretical data that are based on, but unique from, the observable universe. In this study, we created and tested a custom peptide generative adversarial network intended to design peptide sequences that can fold into the β-hairpin secondary structure. This deep neural network model is designed to establish a preliminary foundation of the generative approach based on physicochemical and conformational properties of 20 canonical amino acids, for example, hydrophobicity and residue volume, using extant structure-specific sequence data from the PDB. The beta generative adversarial network model robustly distinguishes secondary structures of β hairpin from α helix and intrinsically disordered peptides with an accuracy of up to 96% and generates artificial β-hairpin peptide sequences with minimum sequence identities around 31% and 50% when compared against the current NCBI PDB and nonredundant databases, respectively. These results highlight the potential of generative models specifically anchored by physicochemical and conformational property features of amino acids to expand the sequence-to-structure landscape of proteins beyond evolutionary limits.
Collapse
Affiliation(s)
- Vardhan Satalkar
- School of Biological Sciences, Georgia Institute of Technology, Atlanta, Georgia
| | - Gemechis D Degaga
- Biosciences Division, Oak Ridge National Laboratory, Oak Ridge, Tennessee
| | - Wei Li
- School of Biological Sciences, Georgia Institute of Technology, Atlanta, Georgia
| | - Yui Tik Pang
- School of Physics, Georgia Institute of Technology, Atlanta, Georgia
| | - Andrew C McShan
- School of Chemistry and Biochemistry, Georgia Institute of Technology, Atlanta, Georgia
| | - James C Gumbart
- School of Physics, Georgia Institute of Technology, Atlanta, Georgia; School of Chemistry and Biochemistry, Georgia Institute of Technology, Atlanta, Georgia
| | - Julie C Mitchell
- Biosciences Division, Oak Ridge National Laboratory, Oak Ridge, Tennessee.
| | - Matthew P Torres
- School of Biological Sciences, Georgia Institute of Technology, Atlanta, Georgia; School of Chemistry and Biochemistry, Georgia Institute of Technology, Atlanta, Georgia.
| |
Collapse
|
58
|
Nowak D, Huczyński A, Bachorz RA, Hoffmann M. Machine Learning Application for Medicinal Chemistry: Colchicine Case, New Structures, and Anticancer Activity Prediction. Pharmaceuticals (Basel) 2024; 17:173. [PMID: 38399388 PMCID: PMC10892630 DOI: 10.3390/ph17020173] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2023] [Revised: 01/02/2024] [Accepted: 01/12/2024] [Indexed: 02/25/2024] Open
Abstract
In the contemporary era, the exploration of machine learning (ML) has gained widespread attention and is being leveraged to augment traditional methodologies in quantitative structure-activity relationship (QSAR) investigations. The principal objective of this research was to assess the anticancer potential of colchicine-based compounds across five distinct cell lines. This research endeavor ultimately sought to construct ML models proficient in forecasting anticancer activity as quantified by the IC50 value, while concurrently generating innovative colchicine-derived compounds. The resistance index (RI) is computed to evaluate the drug resistance exhibited by LoVo/DX cells relative to LoVo cancer cell lines. Meanwhile, the selectivity index (SI) is computed to determine the potential of a compound to demonstrate superior efficacy against tumor cells compared to its toxicity against normal cells, such as BALB/3T3. We introduce a novel ML system adept at recommending novel chemical structures predicated on known anticancer activity. Our investigation entailed the assessment of inhibitory capabilities across five cell lines, employing predictive models utilizing various algorithms, including random forest, decision tree, support vector machines, k-nearest neighbors, and multiple linear regression. The most proficient model, as determined by quality metrics, was employed to predict the anticancer activity of novel colchicine-based compounds. This methodological approach yielded the establishment of a library encompassing new colchicine-based compounds, each assigned an IC50 value. Additionally, this study resulted in the development of a validated predictive model, capable of reasonably estimating IC50 values based on molecular structure input.
Collapse
Affiliation(s)
- Damian Nowak
- Department of Quantum Chemistry, Faculty of Chemistry, Adam Mickiewicz University in Poznan, Uniwersytetu Poznanskiego 8, 61-614 Poznan, Poland
| | - Adam Huczyński
- Department of Medical Chemistry, Faculty of Chemistry, Adam Mickiewicz University in Poznan, Uniwersytetu Poznanskiego 8, 61-614 Poznan, Poland;
| | - Rafał Adam Bachorz
- Institute of Medical Biology of Polish Academy of Sciences, Lodowa 106, 93-232 Lodz, Poland;
- Institute of Computing Science, Faculty of Computing, Poznań University of Technology, Piotrowo 2, 60-965 Poznań, Poland
| | - Marcin Hoffmann
- Department of Quantum Chemistry, Faculty of Chemistry, Adam Mickiewicz University in Poznan, Uniwersytetu Poznanskiego 8, 61-614 Poznan, Poland
| |
Collapse
|
59
|
Weng G, Zhao H, Nie D, Zhang H, Liu L, Hou T, Kang Y. RediscMol: Benchmarking Molecular Generation Models in Biological Properties. J Med Chem 2024; 67:1533-1543. [PMID: 38181194 DOI: 10.1021/acs.jmedchem.3c02051] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2024]
Abstract
Deep learning-based molecular generative models have garnered emerging attention for their capability to generate molecules with novel structures and desired physicochemical properties. However, the evaluation of these models, particularly in a biological context, remains insufficient. To address the limitations of existing metrics and emulate practical application scenarios, we construct the RediscMol benchmark that comprises active molecules extracted from 5 kinase and 3 GPCR data sets. A set of rediscovery- and similarity-related metrics are introduced to assess the performance of 8 representative generative models (CharRNN, VAE, Reinvent, AAE, ORGAN, RNNAttn, TransVAE, and GraphAF). Our findings based on the RediscMol benchmark differ from those of previous evaluations. CharRNN, VAE, and Reinvent exhibit a greater ability to reproduce known active molecules, while RNNAttn, TransVAE, and GraphAF struggle in this aspect despite their notable performance on commonly used distribution-learning metrics. Our evaluation framework may provide valuable guidance for advancing generative models in real-world drug design scenarios.
Collapse
Affiliation(s)
- Gaoqi Weng
- Innovation Institute for Artificial Intelligence in Medicine of Zhejiang University, College of Pharmaceutical Sciences, Zhejiang UniversityHangzhou 310058, Zhejiang, China
| | - Huifeng Zhao
- Innovation Institute for Artificial Intelligence in Medicine of Zhejiang University, College of Pharmaceutical Sciences, Zhejiang UniversityHangzhou 310058, Zhejiang, China
| | - Dou Nie
- Innovation Institute for Artificial Intelligence in Medicine of Zhejiang University, College of Pharmaceutical Sciences, Zhejiang UniversityHangzhou 310058, Zhejiang, China
| | - Haotian Zhang
- Innovation Institute for Artificial Intelligence in Medicine of Zhejiang University, College of Pharmaceutical Sciences, Zhejiang UniversityHangzhou 310058, Zhejiang, China
| | - Liwei Liu
- Advanced Computing and Storage Laboratory, Central Research Institute, 2012 Laboratories, Huawei Technologies Co., Ltd., Shenzhen 518129, Guangdong, China
| | - Tingjun Hou
- Innovation Institute for Artificial Intelligence in Medicine of Zhejiang University, College of Pharmaceutical Sciences, Zhejiang UniversityHangzhou 310058, Zhejiang, China
| | - Yu Kang
- Innovation Institute for Artificial Intelligence in Medicine of Zhejiang University, College of Pharmaceutical Sciences, Zhejiang UniversityHangzhou 310058, Zhejiang, China
| |
Collapse
|
60
|
Chowdhury J, Fricke C, Bamidele O, Bello M, Yang W, Heyden A, Terejanu G. Invariant Molecular Representations for Heterogeneous Catalysis. J Chem Inf Model 2024; 64:327-339. [PMID: 38197612 PMCID: PMC10806804 DOI: 10.1021/acs.jcim.3c00594] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2023] [Revised: 12/25/2023] [Accepted: 12/28/2023] [Indexed: 01/11/2024]
Abstract
Catalyst screening is a critical step in the discovery and development of heterogeneous catalysts, which are vital for a wide range of chemical processes. In recent years, computational catalyst screening, primarily through density functional theory (DFT), has gained significant attention as a method for identifying promising catalysts. However, the computation of adsorption energies for all likely chemical intermediates present in complex surface chemistries is computationally intensive and costly due to the expensive nature of these calculations and the intrinsic idiosyncrasies of the methods or data sets used. This study introduces a novel machine learning (ML) method to learn adsorption energies from multiple DFT functionals by using invariant molecular representations (IMRs). To do this, we first extract molecular fingerprints for the reaction intermediates and later use a Siamese-neural-network-based training strategy to learn invariant molecular representations or the IMR across all available functionals. Our Siamese network-based representations demonstrate superior performance in predicting adsorption energies compared with other molecular representations. Notably, when considering mean absolute values of adsorption energies as 0.43 eV (PBE-D3), 0.46 eV (BEEF-vdW), 0.81 eV (RPBE), and 0.37 eV (scan+rVV10), our IMR method has achieved the lowest mean absolute errors (MAEs) of 0.18 0.10, 0.16, and 0.18 eV, respectively. These results emphasize the superior predictive capacity of our Siamese network-based representations. The empirical findings in this study illuminate the efficacy, robustness, and dependability of our proposed ML paradigm in predicting adsorption energies, specifically for propane dehydrogenation on a platinum catalyst surface.
Collapse
Affiliation(s)
- Jawad Chowdhury
- Department
of Computer Science, University of North
Carolina at Charlotte, Charlotte, North Carolina 28223, United States
| | - Charles Fricke
- Department
of Chemical Engineering, University of South
Carolina, Columbia, South Carolina 29208, United States
| | - Olajide Bamidele
- Department
of Chemical Engineering, University of South
Carolina, Columbia, South Carolina 29208, United States
| | - Mubarak Bello
- Department
of Chemical Engineering, University of South
Carolina, Columbia, South Carolina 29208, United States
| | - Wenqiang Yang
- Department
of Chemical Engineering, University of South
Carolina, Columbia, South Carolina 29208, United States
| | - Andreas Heyden
- Department
of Chemical Engineering, University of South
Carolina, Columbia, South Carolina 29208, United States
| | - Gabriel Terejanu
- Department
of Computer Science, University of North
Carolina at Charlotte, Charlotte, North Carolina 28223, United States
| |
Collapse
|
61
|
Qian Y, Shi M, Zhang Q. CONSMI: Contrastive Learning in the Simplified Molecular Input Line Entry System Helps Generate Better Molecules. Molecules 2024; 29:495. [PMID: 38276573 PMCID: PMC10821140 DOI: 10.3390/molecules29020495] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2023] [Revised: 01/12/2024] [Accepted: 01/16/2024] [Indexed: 01/27/2024] Open
Abstract
In recent years, the application of deep learning in molecular de novo design has gained significant attention. One successful approach involves using SMILES representations of molecules and treating the generation task as a text generation problem, yielding promising results. However, the generation of more effective and novel molecules remains a key research area. Due to the fact that a molecule can have multiple SMILES representations, it is not sufficient to consider only one of them for molecular generation. To make up for this deficiency, and also motivated by the advancements in contrastive learning in natural language processing, we propose a contrastive learning framework called CONSMI to learn more comprehensive SMILES representations. This framework leverages different SMILES representations of the same molecule as positive examples and other SMILES representations as negative examples for contrastive learning. The experimental results of generation tasks demonstrate that CONSMI significantly enhances the novelty of generated molecules while maintaining a high validity. Moreover, the generated molecules have similar chemical properties compared to the original dataset. Additionally, we find that CONSMI can achieve favorable results in classifier tasks, such as the compound-protein interaction task.
Collapse
Affiliation(s)
| | | | - Qian Zhang
- School of Computer Science and Technology, Shanghai Frontiers Science Center of Molecule Intelligent Syntheses, East China Normal University, 3663 North Zhongshan Road, Putuo District, Shanghai 200062, China; (Y.Q.); (M.S.)
| |
Collapse
|
62
|
Macedo B, Ribeiro Vaz I, Taveira Gomes T. MedGAN: optimized generative adversarial network with graph convolutional networks for novel molecule design. Sci Rep 2024; 14:1212. [PMID: 38216614 PMCID: PMC10786821 DOI: 10.1038/s41598-023-50834-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2023] [Accepted: 12/26/2023] [Indexed: 01/14/2024] Open
Abstract
Generative Artificial Intelligence can be an important asset in the drug discovery process to meet the demand for novel medicines. This work outlines the optimization and fine-tuning steps of MedGAN, a deep learning model based on Wasserstein Generative Adversarial Networks and Graph Convolutional Networks, developed to generate new quinoline-scaffold molecules from complex molecular graphs, including hyperparameter adjustments and evaluations of drug-likeness attributes such as pharmacokinetics, toxicity, and synthetic accessibility. The best model was capable of generating 25% valid molecules, 62% fully connected, from which 92% were quinolines, 93% were novel, and 95% unique, preserving chirality, atom charge, and favorable drug-like properties while generating 4831 novel quinolines. These results provide valuable insights into how activation functions, optimizers, learning rates, neuron units, molecule size and constitution, and scaffold structure affect the performance of generative models and their potential to create new molecular structures, enhancing deep learning applications in computational drug design.
Collapse
Affiliation(s)
- Bruno Macedo
- Faculty of Medicine, University of Porto, Porto, Portugal.
- MedFacts Lda., Lisbon, Portugal.
| | - Inês Ribeiro Vaz
- Faculty of Medicine, University of Porto, Porto, Portugal
- Department of Community Medicine, Information and Decision in Health, Faculty of Medicine, University of Porto, Porto, Portugal
- Center for Health Technology and Services Research (CINTESIS), Porto, Portugal
| | - Tiago Taveira Gomes
- Faculty of Medicine, University of Porto, Porto, Portugal
- Department of Community Medicine, Information and Decision in Health, Faculty of Medicine, University of Porto, Porto, Portugal
- Faculty of Health Sciences, University Fernando Pessoa, Porto, Portugal
- SIGIL Scientific Enterprises, Dubai, UAE
| |
Collapse
|
63
|
Melancon K, Pliushcheuskaya P, Meiler J, Künze G. Targeting ion channels with ultra-large library screening for hit discovery. Front Mol Neurosci 2024; 16:1336004. [PMID: 38249296 PMCID: PMC10796734 DOI: 10.3389/fnmol.2023.1336004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2023] [Accepted: 12/05/2023] [Indexed: 01/23/2024] Open
Abstract
Ion channels play a crucial role in a variety of physiological and pathological processes, making them attractive targets for drug development in diseases such as diabetes, epilepsy, hypertension, cancer, and chronic pain. Despite the importance of ion channels in drug discovery, the vastness of chemical space and the complexity of ion channels pose significant challenges for identifying drug candidates. The use of in silico methods in drug discovery has dramatically reduced the time and cost of drug development and has the potential to revolutionize the field of medicine. Recent advances in computer hardware and software have enabled the screening of ultra-large compound libraries. Integration of different methods at various scales and dimensions is becoming an inevitable trend in drug development. In this review, we provide an overview of current state-of-the-art computational chemistry methodologies for ultra-large compound library screening and their application to ion channel drug discovery research. We discuss the advantages and limitations of various in silico techniques, including virtual screening, molecular mechanics/dynamics simulations, and machine learning-based approaches. We also highlight several successful applications of computational chemistry methodologies in ion channel drug discovery and provide insights into future directions and challenges in this field.
Collapse
Affiliation(s)
- Kortney Melancon
- Department of Chemistry, Vanderbilt University, Nashville, TN, United States
- Center for Structural Biology, Vanderbilt University, Nashville, TN, United States
| | | | - Jens Meiler
- Department of Chemistry, Vanderbilt University, Nashville, TN, United States
- Center for Structural Biology, Vanderbilt University, Nashville, TN, United States
- Medical Faculty, Institute for Drug Discovery, Leipzig University, Leipzig, Germany
- Center for Scalable Data Analytics and Artificial Intelligence, Leipzig University, Leipzig, Germany
| | - Georg Künze
- Medical Faculty, Institute for Drug Discovery, Leipzig University, Leipzig, Germany
- Center for Scalable Data Analytics and Artificial Intelligence, Leipzig University, Leipzig, Germany
- Interdisciplinary Center for Bioinformatics, Leipzig University, Leipzig, Germany
| |
Collapse
|
64
|
Mehrzadi A, Rezaee E, Gharaghani S, Fakhar Z, Mirhosseini SM. A Molecular Generative Model of COVID-19 Main Protease Inhibitors Using Long Short-Term Memory-Based Recurrent Neural Network. J Comput Biol 2024; 31:83-98. [PMID: 38054946 DOI: 10.1089/cmb.2023.0064] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/07/2023] Open
Abstract
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a serious threat to public health and prompted researchers to find anti-coronavirus 2019 (COVID-19) compounds. In this study, the long short-term memory-based recurrent neural network was used to generate new inhibitors for the coronavirus. First, the model was trained to generate drug compounds in the form of valid simplified molecular-input line-entry system strings. Then, the structures of COVID-19 main protease inhibitors were applied to fine-tune the model. After fine-tuning, the network could generate new molecular structures as novel SARS-CoV-2 main protease inhibitors. Molecular docking exhibited that some generated compounds have the proper affinity to the active site of the protease. Molecular Dynamics simulations explored binding free energies of the compounds over simulation trajectories. In addition, in silico absorption, distribution, metabolism, and excretion studies showed that some novel compounds could be formulated as orally active agents. Based on molecular docking and molecular dynamics simulation studies, compound AADH possessed significant binding affinity and presumably inhibition against the SARS-CoV-2 main protease enzyme. Therefore, the proposed deep learning-based model was capable of generating promising anti-COVID-19 drugs.
Collapse
Affiliation(s)
- Arash Mehrzadi
- Department of Electrical, Computer and IT Engineering, Qazvin Branch, Islamic Azad University, Qazvin, Iran
| | - Elham Rezaee
- Department of Pharmaceutical Chemistry, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - Sajjad Gharaghani
- Department of Bioinformatics, Laboratory of Bioinformatics and Drug Design (LBD), University of Tehran, Tehran, Iran
| | - Zeynab Fakhar
- Department of Bioinformatics, Laboratory of Bioinformatics and Drug Design (LBD), University of Tehran, Tehran, Iran
| | | |
Collapse
|
65
|
Olmedo DA, Durant-Archibold AA, López-Pérez JL, Medina-Franco JL. Design and Diversity Analysis of Chemical Libraries in Drug Discovery. Comb Chem High Throughput Screen 2024; 27:502-515. [PMID: 37409545 DOI: 10.2174/1386207326666230705150110] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2023] [Revised: 05/30/2023] [Accepted: 05/30/2023] [Indexed: 07/07/2023]
Abstract
Chemical libraries and compound data sets are among the main inputs to start the drug discovery process at universities, research institutes, and the pharmaceutical industry. The approach used in the design of compound libraries, the chemical information they possess, and the representation of structures, play a fundamental role in the development of studies: chemoinformatics, food informatics, in silico pharmacokinetics, computational toxicology, bioinformatics, and molecular modeling to generate computational hits that will continue the optimization process of drug candidates. The prospects for growth in drug discovery and development processes in chemical, biotechnological, and pharmaceutical companies began a few years ago by integrating computational tools with artificial intelligence methodologies. It is anticipated that it will increase the number of drugs approved by regulatory agencies shortly.
Collapse
Affiliation(s)
- Dionisio A Olmedo
- Centro de Investigaciones Farmacognósticas de la Flora Panameña (CIFLORPAN), Facultad de Farmacia, Universidad de Panamá, Ciudad de Panamá, Apartado, 0824-00178, Panamá
- Sistema Nacional de Investigación (SNI), Secretaria Nacional de Ciencia, Tecnología e Innovación (SENACYT), Ciudad del Saber, Clayton, Panamá
| | - Armando A Durant-Archibold
- Centro de Biodiversidad y Descubrimiento de Drogas, Instituto de Investigaciones Científicas y Servicios de Alta Tecnología (INDICASAT AIP), Apartado, 0843-01103, Panamá
- Departamento de Bioquímica, Facultad de Ciencias Naturales, Exactas y Tecnología, Universidad de Panamá, Ciudad de Panamá, Panamá
| | - José Luis López-Pérez
- CESIFAR, Departamento de Farmacología, Facultad de Medicina, Universidad de Panamá, Ciudad de Panamá, Panamá
- Departamento de Ciencias Farmacéuticas, Facultad de Farmacia, Universidad de Salamanca, Avda. Campo Charro s/n, 37071 Salamanca, España
| | - José Luis Medina-Franco
- DIFACQUIM Grupo de Investigación, Departamento de Farmacia, Escuela de Química, Universidad Nacional Autónoma de México, Ciudad de México, Apartado, 04510, México
| |
Collapse
|
66
|
Bajorath J. Chemical language models for molecular design. Mol Inform 2024; 43:e202300288. [PMID: 38010610 DOI: 10.1002/minf.202300288] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2023] [Revised: 11/22/2023] [Accepted: 11/23/2023] [Indexed: 11/29/2023]
Abstract
In drug discovery, chemical language models (CLMs) originating from natural language processing offer new opportunities for molecular design. CLMs have been developed using recurrent neural network (RNN) or transformer architectures. For the predictive performance of RNN-based encoder-decoder frameworks and transformers, attention mechanisms play a central role. Among others, emerging application areas for CLMs include constrained generative modeling and the prediction of chemical reactions or drug-target interactions. Since CLMs are applicable to any compound or target data that can be presented in a sequential format and tokenized, mappings of different types of sequences can be learned. For example, active compounds can be predicted from protein sequence motifs. Novel off-the-beat-path applications can also be considered. For example, analogue series from medicinal chemistry can be perceived and represented as chemical sequences and extended with new compounds using CLMs. Herein, methodological features of CLMs and different applications are discussed.
Collapse
Affiliation(s)
- Jürgen Bajorath
- Department of Life Science Informatics, Bonn-Aachen International Center for Information Technology, Rheinische Friedrich-Wilhelms-Universität Bonn, Friedrich-Hirzebruch-Allee 5/6, D-53115, Bonn, Germany
- Lamarr Institute for Machine Learning and Artificial Intelligence, Rheinische Friedrich-Wilhelms-Universität Bonn, Friedrich-Hirzebruch-Allee 5/6, D-53115, Bonn, Germany
| |
Collapse
|
67
|
Zhou Q, Chen X. Probabilistic neural network based visual data mining for the healthcare sector. Technol Health Care 2024; 32:1881-1896. [PMID: 38073351 DOI: 10.3233/thc-230980] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/12/2024]
Abstract
BACKGROUND The need for personalised care in the long-term management of patient health is paramount due to the variability in individual features and responses to specific medication. With the availability of large quantities of electronic patient records, big data analysis presents a valuable opportunity to gain insights into disease presentation and patient impact. OBJECTIVE This study aims to utilise data science in the medical field to extract unknown information from databases, validate previously obtained data, and enhance personalised patient care. METHODS An analytics suite is developed for monitoring patient health and treating cholesterol, thyroid, and diabetes disorders. This suite employs exploratory, predictive, and visual analytics to categorise patient data into multiple tiers and forecast related complication risk and treatment response. RESULTS The study found that the analytics suite could successfully identify correlations between various biological indicators of patients and disorders. The suite also showcased potential in predicting health risks and responses to treatments. CONCLUSION The analytics employed in this study suggest advanced methods of data analysis, which could serve as potential decision-making tools for healthcare providers. These methods might lead to improved treatment outcomes, contributing significantly to personalised patient care.
Collapse
Affiliation(s)
- Quan Zhou
- Department of Information, Joint Logistic Support Force 990th Hospital, Zhumadian, Henan, China
| | - Xurui Chen
- Department of Information Technology, Shenzhen Longhua District Central Hospital, Shenzhen, Guangdong, China
| |
Collapse
|
68
|
Seo S, Lee JW. Applications of Big Data and AI-Driven Technologies in CADD (Computer-Aided Drug Design). Methods Mol Biol 2024; 2714:295-305. [PMID: 37676605 DOI: 10.1007/978-1-0716-3441-7_16] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/08/2023]
Abstract
In the field of computer-aided drug design (CADD), there has been dramatic progress in the development of big data and AI-driven methodologies. The expensive and time-consuming process of drug design is related to biomedical complexity. CADD can be used to apply effective and efficient strategies to overcome obstacles in the field of drug design in order to properly design and develop a new medicine. To prepare the raw data for consistent and repeatable applications of big data and AI methodologies, data pre-processing methods are introduced. Big data and AI technologies can be used to develop drugs in areas including predicting absorption, distribution, metabolism, excretion, and toxicity properties as well as finding binding sites in target proteins and conducting structure-based virtual screenings. The accurate and thorough analysis of large amounts of biomedical data as well as the design of prediction models in the area of drug design is made possible by data pre-processing and applications of big data and AI skills. In the biomedical big data era, knowledge on the biological, chemical, or pharmacological structures of biomedical entities relevant to drug design should be analyzed with significant big data and AI approaches.
Collapse
Affiliation(s)
- Seongmin Seo
- Department of Mechanical Engineering, Ulsan National Institute of Science and Technology, Ulsan, Republic of Korea
| | - Jai Woo Lee
- Department of Big Data Science, College of Public Policy, Korea University, Sejong, Republic of Korea.
| |
Collapse
|
69
|
Huang CH, Lin ST. MARS Plus: An Improved Molecular Design Tool for Complex Compounds Involving Ionic, Stereo, and Cis-Trans Isomeric Structures. J Chem Inf Model 2023; 63:7711-7728. [PMID: 38100117 DOI: 10.1021/acs.jcim.3c01745] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2023]
Abstract
MARS (Molecular Assembling and Representation Suite) (Hsu et al. J. Chem. Inf. Model. 2019, 59, 3703-3713) is a toolbox for the molecular design of organic molecules. MARS uses integer arrays to represent the elements and connectivity between elements of a molecule. It provides a collection of operations to manipulate the elemental composition and connectivity of a molecule (or a pair of molecules), enabling the creation of novel chemical compounds. In this work, the original MARS is extended to handle complex molecular structures, including geometric (cis-trans) isomers, stereo isomers, cyclic compounds, and ionic species. The extended version of MARS, referred to as MARS+, has a more comprehensive coverage of the chemical space and therefore can explore molecules with a greater chemical and physical diversity. Compared to other molecular design tools, MARS+ is designed to perform all possible manipulations on a given molecule or a pair of molecules. Molecular structure manipulation can be conducted in either a controlled or a random fashion. Furthermore, every structure manipulation has a counterpart so that the operation can be reversed. Nearly any possible chemical structure can be generated with MARS+ via a combination of molecular operations. The capabilities of MARS+ are examined by the design of new ionic liquids (ILs). The results show that MARS+ is a useful tool for computer-aided molecular design (CAMD) and molecular structure enumeration.
Collapse
Affiliation(s)
- Chen-Hsuan Huang
- Department of Chemical Engineering, National Taiwan University, Taipei 10617, Taiwan
| | - Shiang-Tai Lin
- Department of Chemical Engineering, National Taiwan University, Taipei 10617, Taiwan
| |
Collapse
|
70
|
Liu DF, Zhang YX, Dong WZ, Feng QK, Zhong SL, Dang ZM. High-Temperature Polymer Dielectrics Designed Using an Invertible Molecular Graph Generative Model. J Chem Inf Model 2023; 63:7669-7675. [PMID: 38061777 DOI: 10.1021/acs.jcim.3c01572] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2023]
Abstract
Generating new molecules with the desired physical or chemical properties is the key challenge of computational material design. Deep learning techniques are being actively applied in the field of data-driven material informatics and provide a promising way to accelerate the discovery of innovative materials. In this work, we utilize an invertible graph generative model to generate hypothetical promising high-temperature polymer dielectrics. A molecular graph generative model based on the invertible normalizing flow is trained on a data set containing 250k polymer molecular graphs (mostly generated by an RNN-based generative model) to learn the invertible transformations between latent distributions and molecular graph structures. When generating molecular graphs, a sample vector is drawn from the latent space, and then an adjacency tensor and node attribute matrix are generated through two invertible flows in two steps and assembled into a molecular graph. The model has the merits of exact likelihood training and an efficient one-shot generation process. The learned latent space is used to generate polymers with a high glass-transition temperature (Tg) and a wide band gap (Eg) for the application of high-temperature energy storage film capacitors. This work contributes to the efficient design of high-temperature polymer dielectrics by using deep generative models.
Collapse
Affiliation(s)
- Di-Fan Liu
- State Key Laboratory of Power Systems, Department of Electrical Engineering, Tsinghua University, Beijing 100084, People's Republic of China
| | - Yong-Xin Zhang
- State Key Laboratory of Power Systems, Department of Electrical Engineering, Tsinghua University, Beijing 100084, People's Republic of China
| | - Wen-Zhuo Dong
- State Key Laboratory of Power Systems, Department of Electrical Engineering, Tsinghua University, Beijing 100084, People's Republic of China
| | - Qi-Kun Feng
- State Key Laboratory of Power Systems, Department of Electrical Engineering, Tsinghua University, Beijing 100084, People's Republic of China
| | - Shao-Long Zhong
- State Key Laboratory of Power Systems, Department of Electrical Engineering, Tsinghua University, Beijing 100084, People's Republic of China
| | - Zhi-Min Dang
- State Key Laboratory of Power Systems, Department of Electrical Engineering, Tsinghua University, Beijing 100084, People's Republic of China
| |
Collapse
|
71
|
Qin R, Zhang H, Huang W, Shao Z, Lei J. Deep learning-based design and screening of benzimidazole-pyrazine derivatives as adenosine A 2B receptor antagonists. J Biomol Struct Dyn 2023:1-17. [PMID: 38133953 DOI: 10.1080/07391102.2023.2295974] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2023] [Accepted: 12/11/2023] [Indexed: 12/24/2023]
Abstract
The Adenosine A2B receptor (A2BAR) is considered a novel potential target for the immunotherapy of cancer, and A2BAR antagonists have an inhibitory effect on tumor growth, proliferation, and metastasis. In our previous studies, we identified a class of benzimidazole-pyrazine scaffolds whose derivatives exhibited the antagonistic effect but lacked subtype selectivity towards A2BAR. In this work, we developed a scaffold-based protocol that incorporates a deep generative model and multilayer virtual screening to design benzimidazole-pyrazine derivatives as potential selective A2BAR antagonists. By utilizing a generative model with reported A2BAR antagonists as the training set, we built up a scaffold-focused library of benzimidazole-pyrazine derivatives and processed a virtual screening protocol to discover potential A2BAR antagonists. Finally, five molecules with different Bemis-Murcko scaffolds were identified and exhibited higher binding free energies than the reference molecule 12o. Further computational analysis revealed that the 3-benzyl derivative ABA-1266 presented high selectivity toward A2BAR and showed preferred draggability, providing future potent development of selective A2BAR antagonists.Communicated by Ramaswamy H. Sarma.
Collapse
Affiliation(s)
- Rui Qin
- School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, China
- College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China
| | - Hao Zhang
- School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, China
| | - Weifeng Huang
- School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, China
| | - Zhenglin Shao
- School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, China
| | - Jinping Lei
- School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, China
| |
Collapse
|
72
|
Wang F, Pasin D, Skinnider MA, Liigand J, Kleis JN, Brown D, Oler E, Sajed T, Gautam V, Harrison S, Greiner R, Foster LJ, Dalsgaard PW, Wishart DS. Deep Learning-Enabled MS/MS Spectrum Prediction Facilitates Automated Identification Of Novel Psychoactive Substances. Anal Chem 2023; 95:18326-18334. [PMID: 38048435 PMCID: PMC10733899 DOI: 10.1021/acs.analchem.3c02413] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2023] [Revised: 11/10/2023] [Accepted: 11/13/2023] [Indexed: 12/06/2023]
Abstract
The market for illicit drugs has been reshaped by the emergence of more than 1100 new psychoactive substances (NPS) over the past decade, posing a major challenge to the forensic and toxicological laboratories tasked with detecting and identifying them. Tandem mass spectrometry (MS/MS) is the primary method used to screen for NPS within seized materials or biological samples. The most contemporary workflows necessitate labor-intensive and expensive MS/MS reference standards, which may not be available for recently emerged NPS on the illicit market. Here, we present NPS-MS, a deep learning method capable of accurately predicting the MS/MS spectra of known and hypothesized NPS from their chemical structures alone. NPS-MS is trained by transfer learning from a generic MS/MS prediction model on a large data set of MS/MS spectra. We show that this approach enables a more accurate identification of NPS from experimentally acquired MS/MS spectra than any existing method. We demonstrate the application of NPS-MS to identify a novel derivative of phencyclidine (PCP) within an unknown powder seized in Denmark without the use of any reference standards. We anticipate that NPS-MS will allow forensic laboratories to identify more rapidly both known and newly emerging NPS. NPS-MS is available as a web server at https://nps-ms.ca/, which provides MS/MS spectra prediction capabilities for given NPS compounds. Additionally, it offers MS/MS spectra identification against a vast database comprising approximately 8.7 million predicted NPS compounds from DarkNPS and 24.5 million predicted ESI-QToF-MS/MS spectra for these compounds.
Collapse
Affiliation(s)
- Fei Wang
- Department
of Computing Science, University of Alberta, Edmonton, Alberta T6G 2E8, Canada
- Alberta
Machine Intelligence Institute, Edmonton, Alberta T5J
3B1, Canada
| | - Daniel Pasin
- Section
of Forensic Chemistry, Department of Forensic Medicine, University of Copenhagen, Copenhagen 2100, Denmark
| | - Michael A. Skinnider
- Michael
Smith Laboratories, University of British
Columbia, Vancouver, British Columbia V6T 1Z4, Canada
- Lewis-Sigler
Institute for Integrative Genomics, Princeton
University, Princeton, New Jersey 08544, United States
- Ludwig Institute
for Cancer Research, Princeton University, Princeton, New Jersey 08544, United States
| | - Jaanus Liigand
- Department
of Biological Sciences, University of Alberta, Edmonton, Alberta T6G 2E9, Canada
- Institute
of Chemistry, University of Tartu, Tartu 50411, Estonia
| | - Jan-Niklas Kleis
- Institute
of Forensic Medicine, Forensic Toxicology, Johannes Gutenberg University Mainz, Mainz 55131, Germany
| | - David Brown
- Forensic
Science Laboratory, ChemCentre, Bentley, Western Australia 6102, Australia
- School of Molecular and Life Sciences, Curtin University, Bentley, Western Australia 6009, Australia
| | - Eponine Oler
- Department
of Biological Sciences, University of Alberta, Edmonton, Alberta T6G 2E9, Canada
| | - Tanvir Sajed
- Department
of Biological Sciences, University of Alberta, Edmonton, Alberta T6G 2E9, Canada
| | - Vasuk Gautam
- Department
of Biological Sciences, University of Alberta, Edmonton, Alberta T6G 2E9, Canada
| | - Stephen Harrison
- Forensic
Science Laboratory, ChemCentre, Bentley, Western Australia 6102, Australia
| | - Russell Greiner
- Department
of Computing Science, University of Alberta, Edmonton, Alberta T6G 2E8, Canada
- Alberta
Machine Intelligence Institute, Edmonton, Alberta T5J
3B1, Canada
| | - Leonard J. Foster
- Michael
Smith Laboratories, University of British
Columbia, Vancouver, British Columbia V6T 1Z4, Canada
- Department
of Biochemistry and Molecular Biology, University
of British Columbia, Vancouver, British Columbia V6T 2A1, Canada
| | - Petur Weihe Dalsgaard
- Section
of Forensic Chemistry, Department of Forensic Medicine, University of Copenhagen, Copenhagen 2100, Denmark
| | - David S. Wishart
- Department
of Computing Science, University of Alberta, Edmonton, Alberta T6G 2E8, Canada
- Department
of Biological Sciences, University of Alberta, Edmonton, Alberta T6G 2E9, Canada
- Department of Laboratory
Medicine and Pathology, University of Alberta, Edmonton, Alberta T6G 1C9, Canada
- Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta T6G 2C8, Canada
- Biological Sciences Division, Pacific Northwest
National Laboratory, Richland, Washington 99354, United States
| |
Collapse
|
73
|
Bosc N, Felix E, Gardner JMF, Mills J, Timmerman M, Asveld D, Rensen K, Mukherjee P, Das R, Chenu E, Besson D, Burrows JN, Duffy J, Laleu B, Guantai EM, Leach AR. MAIP: An Open-Source Tool to Enrich High-Throughput Screening Output and Identify Novel, Druglike Molecules with Antimalarial Activity. ACS Med Chem Lett 2023; 14:1733-1741. [PMID: 38116432 PMCID: PMC10726451 DOI: 10.1021/acsmedchemlett.3c00369] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2023] [Revised: 10/30/2023] [Accepted: 11/06/2023] [Indexed: 12/21/2023] Open
Abstract
Efforts to tackle malaria must continue for a disease that threatens half of the global population. Parasite resistance to current therapies requires new chemotypes that are able to demonstrate effectiveness and safety. Previously, we developed a machine-learning-based approach to predict compound antimalarial activity, which was trained on the compound collections of several organizations. The resulting prediction platform, MAIP, was made freely available to the scientific community and offers a solution to prioritize molecules of interest in virtual screening and hit-to-lead optimization. Here, we experimentally validate MAIP and demonstrate how the approach was used in combination with a robust compound selection workflow and a recently introduced innovative high-throughput screening (HTS) cascade to select and purchase compounds from a public library for subsequent experimental screening. We observed a 12-fold enrichment compared with a randomly selected set of molecules, and the eight hits we ultimately selected exhibit good potency and absorption, distribution, metabolism, and excretion (ADME) profiles.
Collapse
Affiliation(s)
- Nicolas Bosc
- European
Molecular Biology Laboratory, European Bioinformatics
Institute (EMBL-EBI), Wellcome Genome Campus, Hinxton, Cambridgeshire CB10 1SD, United Kingdom
| | - Eloy Felix
- European
Molecular Biology Laboratory, European Bioinformatics
Institute (EMBL-EBI), Wellcome Genome Campus, Hinxton, Cambridgeshire CB10 1SD, United Kingdom
| | - J. Mark F. Gardner
- AMG
Consultants Ltd, Discovery
Park House, Discovery Park, Sandwich, Kent CT13 9ND, United Kingdom
| | - James Mills
- Sandexis
Medicinal Chemistry Ltd, Innovation House, Discovery Park, Sandwich, Kent CT13 9FF, United Kingdom
| | - Martijn Timmerman
- Pivot
Park Screening Centre, Pivot Park (Frederick Banting Building), Kloosterstraat 9, 5349 AB Oss, The Netherlands
| | - Dennis Asveld
- Pivot
Park Screening Centre, Pivot Park (Frederick Banting Building), Kloosterstraat 9, 5349 AB Oss, The Netherlands
| | - Kim Rensen
- Pivot
Park Screening Centre, Pivot Park (Frederick Banting Building), Kloosterstraat 9, 5349 AB Oss, The Netherlands
| | - Partha Mukherjee
- TCG
Life Sciences, Bengal Intelligent Park Limited, Block EP & GP, Salt Lake Electronics
Complex, Sector V, Kolkata, West Bengal 700091, India
| | - Rishi Das
- TCG
Life Sciences, Bengal Intelligent Park Limited, Block EP & GP, Salt Lake Electronics
Complex, Sector V, Kolkata, West Bengal 700091, India
| | - Elodie Chenu
- Medicines
for Malaria Ventures, 1215 Geneva, Switzerland
| | | | | | - James Duffy
- Medicines
for Malaria Ventures, 1215 Geneva, Switzerland
| | - Benoît Laleu
- Medicines
for Malaria Ventures, 1215 Geneva, Switzerland
| | - Eric M. Guantai
- Department
of Pharmacy, Faculty of Health Sciences, University of Nairobi, 00202 Nairobi, Kenya
| | - Andrew R. Leach
- European
Molecular Biology Laboratory, European Bioinformatics
Institute (EMBL-EBI), Wellcome Genome Campus, Hinxton, Cambridgeshire CB10 1SD, United Kingdom
| |
Collapse
|
74
|
Kyro GW, Morgunov A, Brent RI, Batista VS. ChemSpaceAL: An Efficient Active Learning Methodology Applied to Protein-Specific Molecular Generation. ARXIV 2023:arXiv:2309.05853v2. [PMID: 37744464 PMCID: PMC10516108] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Subscribe] [Scholar Register] [Indexed: 09/26/2023]
Abstract
The incredible capabilities of generative artificial intelligence models have inevitably led to their application in the domain of drug discovery. Within this domain, the vastness of chemical space motivates the development of more efficient methods for identifying regions with molecules that exhibit desired characteristics. In this work, we present a computationally efficient active learning methodology that requires evaluation of only a subset of the generated data in the constructed sample space to successfully align a generative model with respect to a specified objective. We demonstrate the applicability of this methodology to targeted molecular generation by fine-tuning a GPT-based molecular generator toward a protein with FDA-approved small-molecule inhibitors, c-Abl kinase. Remarkably, the model learns to generate molecules similar to the inhibitors without prior knowledge of their existence, and even reproduces two of them exactly. We also show that the methodology is effective for a protein without any commercially available small-molecule inhibitors, the HNH domain of the CRISPR-associated protein 9 (Cas9) enzyme. We believe that the inherent generality of this method ensures that it will remain applicable as the exciting field of in silico molecular generation evolves. To facilitate implementation and reproducibility, we have made all of our software available through the open-source ChemSpaceAL Python package.
Collapse
|
75
|
Zou J, Yu J, Hu P, Zhao L, Shi S. STAGAN: An approach for improve the stability of molecular graph generation based on generative adversarial networks. Comput Biol Med 2023; 167:107691. [PMID: 37976819 DOI: 10.1016/j.compbiomed.2023.107691] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2022] [Revised: 09/18/2023] [Accepted: 11/06/2023] [Indexed: 11/19/2023]
Abstract
With the wide application of deep learning in Drug Discovery, deep generative model has shown its advantages in drug molecular generation. Generative adversarial networks can be used to learn the internal structure of molecules, but the training process may be unstable, such as gradient disappearance and model collapse, which may lead to the generation of molecules that do not conform to chemical rules or a single style. In this paper, a novel method called STAGAN was proposed to solve the difficulty of model training, by adding a new gradient penalty term in the discriminator and designing a parallel layer of batch normalization used in generator. As an illustration of method, STAGAN generated higher valid and unique molecules than previous models in training datasets from QM9 and ZINC-250K. This indicates that the proposed method can effectively solve the instability problem in the model training process, and can provide more instructive guidance for the further study of molecular graph generation.
Collapse
Affiliation(s)
- Jinping Zou
- Department of Mathematics, School of Mathematics and Computer Sciences, Nanchang University, Nanchang, 330031, China; Institute of Mathematics and Interdisciplinary Sciences, Nanchang University, Nanchang, 330031, China
| | - Jialin Yu
- Department of Mathematics, School of Mathematics and Computer Sciences, Nanchang University, Nanchang, 330031, China; Institute of Mathematics and Interdisciplinary Sciences, Nanchang University, Nanchang, 330031, China
| | - Pengwei Hu
- Department of Mathematics, School of Mathematics and Computer Sciences, Nanchang University, Nanchang, 330031, China; Institute of Mathematics and Interdisciplinary Sciences, Nanchang University, Nanchang, 330031, China
| | - Long Zhao
- Department of Mathematics, School of Mathematics and Computer Sciences, Nanchang University, Nanchang, 330031, China; Institute of Mathematics and Interdisciplinary Sciences, Nanchang University, Nanchang, 330031, China
| | - Shaoping Shi
- Department of Mathematics, School of Mathematics and Computer Sciences, Nanchang University, Nanchang, 330031, China; Institute of Mathematics and Interdisciplinary Sciences, Nanchang University, Nanchang, 330031, China.
| |
Collapse
|
76
|
Pereira TO, Abbasi M, Oliveira RI, Guedes RA, Salvador JAR, Arrais JP. Artificial intelligence for prediction of biological activities and generation of molecular hits using stereochemical information. J Comput Aided Mol Des 2023; 37:791-806. [PMID: 37847342 PMCID: PMC10618333 DOI: 10.1007/s10822-023-00539-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2023] [Accepted: 10/02/2023] [Indexed: 10/18/2023]
Abstract
In this work, we develop a method for generating targeted hit compounds by applying deep reinforcement learning and attention mechanisms to predict binding affinity against a biological target while considering stereochemical information. The novelty of this work is a deep model Predictor that can establish the relationship between chemical structures and their corresponding [Formula: see text] values. We thoroughly study the effect of different molecular descriptors such as ECFP4, ECFP6, SMILES and RDKFingerprint. Also, we demonstrated the importance of attention mechanisms to capture long-range dependencies in molecular sequences. Due to the importance of stereochemical information for the binding mechanism, this information was employed both in the prediction and generation processes. To identify the most promising hits, we apply the self-adaptive multi-objective optimization strategy. Moreover, to ensure the existence of stereochemical information, we consider all the possible enumerated stereoisomers to provide the most appropriate 3D structures. We evaluated this approach against the Ubiquitin-Specific Protease 7 (USP7) by generating putative inhibitors for this target. The predictor with SMILES notations as descriptor plus bidirectional recurrent neural network using attention mechanism has the best performance. Additionally, our methodology identify the regions of the generated molecules that are important for the interaction with the receptor's active site. Also, the obtained results demonstrate that it is possible to discover synthesizable molecules with high biological affinity for the target, containing the indication of their optimal stereochemical conformation.
Collapse
Affiliation(s)
- Tiago O Pereira
- Centre for Informatics and Systems, Department of Informatics Engineering, University of Coimbra, Coimbra, Portugal.
| | - Maryam Abbasi
- Centre for Informatics and Systems, Department of Informatics Engineering, University of Coimbra, Coimbra, Portugal
- Applied Research Institute, Polytechnic Institute of Coimbra, Coimbra, Portugal
- Research Centre for Natural Resources Environment and Society (CERNAS), Polytechnic Institute of Coimbra, Coimbra, Portugal
| | - Rita I Oliveira
- Laboratory of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Coimbra, Coimbra, Portugal
- Center for Neuroscience and Cell Biology, Center for Innovative Biomedicine and Biotechnology, Coimbra, Portugal
| | - Romina A Guedes
- Laboratory of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Coimbra, Coimbra, Portugal
- Center for Neuroscience and Cell Biology, Center for Innovative Biomedicine and Biotechnology, Coimbra, Portugal
| | - Jorge A R Salvador
- Laboratory of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Coimbra, Coimbra, Portugal
- Center for Neuroscience and Cell Biology, Center for Innovative Biomedicine and Biotechnology, Coimbra, Portugal
| | - Joel P Arrais
- Centre for Informatics and Systems, Department of Informatics Engineering, University of Coimbra, Coimbra, Portugal
| |
Collapse
|
77
|
Lv Q, Zhou F, Liu X, Zhi L. Artificial intelligence in small molecule drug discovery from 2018 to 2023: Does it really work? Bioorg Chem 2023; 141:106894. [PMID: 37776682 DOI: 10.1016/j.bioorg.2023.106894] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/15/2023] [Revised: 09/24/2023] [Accepted: 09/25/2023] [Indexed: 10/02/2023]
Abstract
Utilizing artificial intelligence (AI) in drug design represents an advanced approach for identifying targets and developing new drugs. Integrating AI techniques significantly reduces the workload involved in drug development and enhances the efficiency of early-stage drug discovery. This review aims to present a comprehensive overview of the utilization of AI methods in the field of small drug design, with a specific focus on four key areas: protein structure prediction, molecular virtual screening, molecular design, and absorption, distribution, metabolism, excretion, and toxicity (ADMET) prediction. Additionally, the role and limitations of AI in drug development are explored, and the impact of AI on decision-making processes is studied. It is important to note that while AI can bring numerous benefits to the early stage of drug development, the direction and quality of decision-making should still be emphasized, as AI should be considered as a tool rather than a decisive factor.
Collapse
Affiliation(s)
- Qi Lv
- School of Pharmacy, Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Hefei 230032, PR China
| | - Feilong Zhou
- School of Pharmacy, Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Hefei 230032, PR China
| | - Xinhua Liu
- School of Pharmacy, Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Hefei 230032, PR China.
| | - Liping Zhi
- School of Health Management, Anhui Medical University Hefei, 230032, PR China.
| |
Collapse
|
78
|
Xu M, Chen H. Tree-Invent: A Novel Multipurpose Molecular Generative Model Constrained with a Topological Tree. J Chem Inf Model 2023; 63:7067-7082. [PMID: 37962855 DOI: 10.1021/acs.jcim.3c01626] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2023]
Abstract
De novo molecular design plays an important role in drug discovery. Here, a novel generative model, Tree-Invent, was proposed to integrate topological constraints in the generation of a molecular graph. In this model, a molecular graph is represented as a topological tree in which a ring system, a nonring atom, and a chemical bond are regarded as the ring node, single node, and edge, respectively. The molecule generation is driven by three independent submodels for carrying out operations of node addition, ring generation, and node connection. One unique feature of the generative model is that the topological tree structure can be specified as a constraint for structure generation, which provides more precise control of structure generation. Combined with reinforcement learning, the Tree-Invent model could efficiently explore targeted chemical space. Moreover, the Tree-Invent model is flexible enough to be used in versatile molecule design settings such as scaffold decoration, scaffold hopping, and linker generation.
Collapse
Affiliation(s)
- Mingyuan Xu
- Guangzhou National Laboratory, No. 9 XingDaoHuanBei Road, Guangzhou International Bio Island, Guangzhou, Guangdong 510005, China
| | - Hongming Chen
- Guangzhou National Laboratory, No. 9 XingDaoHuanBei Road, Guangzhou International Bio Island, Guangzhou, Guangdong 510005, China
| |
Collapse
|
79
|
Lu H, Wei Z, Wang X, Zhang K, Liu H. GraphGPT: A Graph Enhanced Generative Pretrained Transformer for Conditioned Molecular Generation. Int J Mol Sci 2023; 24:16761. [PMID: 38069085 PMCID: PMC10706000 DOI: 10.3390/ijms242316761] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2023] [Revised: 11/16/2023] [Accepted: 11/23/2023] [Indexed: 12/18/2023] Open
Abstract
Condition-based molecular generation can generate a large number of molecules with particular properties, expanding the virtual drug screening library, and accelerating the process of drug discovery. In this study, we combined a molecular graph structure and sequential representations using a generative pretrained transformer (GPT) architecture for generating molecules conditionally. The incorporation of graph structure information facilitated a better comprehension of molecular topological features, and the augmentation of a sequential contextual understanding of GPT architecture facilitated molecular generation. The experiments indicate that our model efficiently produces molecules with the desired properties, with valid and unique metrics that are close to 100%. Faced with the typical task of generating molecules based on a scaffold in drug discovery, our model is able to preserve scaffold information and generate molecules with low similarity and specified properties.
Collapse
Affiliation(s)
| | | | | | | | - Hao Liu
- College of Computer Science and Technology, Ocean University of China, Qingdao 266100, China
| |
Collapse
|
80
|
Handa K, Thomas MC, Kageyama M, Iijima T, Bender A. On the difficulty of validating molecular generative models realistically: a case study on public and proprietary data. J Cheminform 2023; 15:112. [PMID: 37990215 PMCID: PMC10664602 DOI: 10.1186/s13321-023-00781-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2023] [Accepted: 11/10/2023] [Indexed: 11/23/2023] Open
Abstract
While a multitude of deep generative models have recently emerged there exists no best practice for their practically relevant validation. On the one hand, novel de novo-generated molecules cannot be refuted by retrospective validation (so that this type of validation is biased); but on the other hand prospective validation is expensive and then often biased by the human selection process. In this case study, we frame retrospective validation as the ability to mimic human drug design, by answering the following question: Can a generative model trained on early-stage project compounds generate middle/late-stage compounds de novo? To this end, we used experimental data that contains the elapsed time of a synthetic expansion following hit identification from five public (where the time series was pre-processed to better reflect realistic synthetic expansions) and six in-house project datasets, and used REINVENT as a widely adopted RNN-based generative model. After splitting the dataset and training REINVENT on early-stage compounds, we found that rediscovery of middle/late-stage compounds was much higher in public projects (at 1.60%, 0.64%, and 0.21% of the top 100, 500, and 5000 scored generated compounds) than in in-house projects (where the values were 0.00%, 0.03%, and 0.04%, respectively). Similarly, average single nearest neighbour similarity between early- and middle/late-stage compounds in public projects was higher between active compounds than inactive compounds; however, for in-house projects the converse was true, which makes rediscovery (if so desired) more difficult. We hence show that the generative model recovers very few middle/late-stage compounds from real-world drug discovery projects, highlighting the fundamental difference between purely algorithmic design and drug discovery as a real-world process. Evaluating de novo compound design approaches appears, based on the current study, difficult or even impossible to do retrospectively.Scientific Contribution This contribution hence illustrates aspects of evaluating the performance of generative models in a real-world setting which have not been extensively described previously and which hopefully contribute to their further future development.
Collapse
Affiliation(s)
- Koichi Handa
- Centre for Molecular Informatics, Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge, CB2 1EW, UK.
- Toxicology & DMPK Research Department, Teijin Institute for Bio-Medical Research, Teijin Pharma Limited, 4-3-2 Asahigaoka, Hino-Shi, Tokyo, 191-8512, Japan.
| | - Morgan C Thomas
- Centre for Molecular Informatics, Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge, CB2 1EW, UK
| | - Michiharu Kageyama
- Toxicology & DMPK Research Department, Teijin Institute for Bio-Medical Research, Teijin Pharma Limited, 4-3-2 Asahigaoka, Hino-Shi, Tokyo, 191-8512, Japan
| | - Takeshi Iijima
- Toxicology & DMPK Research Department, Teijin Institute for Bio-Medical Research, Teijin Pharma Limited, 4-3-2 Asahigaoka, Hino-Shi, Tokyo, 191-8512, Japan
| | - Andreas Bender
- Centre for Molecular Informatics, Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge, CB2 1EW, UK.
| |
Collapse
|
81
|
Ochiai T, Inukai T, Akiyama M, Furui K, Ohue M, Matsumori N, Inuki S, Uesugi M, Sunazuka T, Kikuchi K, Kakeya H, Sakakibara Y. Variational autoencoder-based chemical latent space for large molecular structures with 3D complexity. Commun Chem 2023; 6:249. [PMID: 37973971 PMCID: PMC10654724 DOI: 10.1038/s42004-023-01054-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2023] [Accepted: 11/06/2023] [Indexed: 11/19/2023] Open
Abstract
The structural diversity of chemical libraries, which are systematic collections of compounds that have potential to bind to biomolecules, can be represented by chemical latent space. A chemical latent space is a projection of a compound structure into a mathematical space based on several molecular features, and it can express structural diversity within a compound library in order to explore a broader chemical space and generate novel compound structures for drug candidates. In this study, we developed a deep-learning method, called NP-VAE (Natural Product-oriented Variational Autoencoder), based on variational autoencoder for managing hard-to-analyze datasets from DrugBank and large molecular structures such as natural compounds with chirality, an essential factor in the 3D complexity of compounds. NP-VAE was successful in constructing the chemical latent space from large-sized compounds that were unable to be handled in existing methods, achieving higher reconstruction accuracy, and demonstrating stable performance as a generative model across various indices. Furthermore, by exploring the acquired latent space, we succeeded in comprehensively analyzing a compound library containing natural compounds and generating novel compound structures with optimized functions.
Collapse
Grants
- 22H04901 Ministry of Education, Culture, Sports, Science and Technology (MEXT)
- 17H06410 Ministry of Education, Culture, Sports, Science and Technology (MEXT)
- 23H04885 Ministry of Education, Culture, Sports, Science and Technology (MEXT)
- 23H04880 Ministry of Education, Culture, Sports, Science and Technology (MEXT)
- 23H04881 Ministry of Education, Culture, Sports, Science and Technology (MEXT)
- 23H04887 Ministry of Education, Culture, Sports, Science and Technology (MEXT)
Collapse
Affiliation(s)
- Toshiki Ochiai
- Department of Biosciences and Informatics, Keio University, Yokohama, Kanagawa, 223-8522, Japan
| | - Tensei Inukai
- Department of Biosciences and Informatics, Keio University, Yokohama, Kanagawa, 223-8522, Japan
| | - Manato Akiyama
- Department of Biosciences and Informatics, Keio University, Yokohama, Kanagawa, 223-8522, Japan
| | - Kairi Furui
- Department of Computer Science, School of Computing, Tokyo Institute of Technology, Yokohama, Kanagawa, 226-8501, Japan
| | - Masahito Ohue
- Department of Computer Science, School of Computing, Tokyo Institute of Technology, Yokohama, Kanagawa, 226-8501, Japan
| | - Nobuaki Matsumori
- Department of Chemistry, Graduate School of Science, Kyushu University, Fukuoka, Fukuoka, 819-0395, Japan
| | - Shinsuke Inuki
- Division of Medicinal Frontier Sciences, Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, Kyoto, 606-8501, Japan
| | - Motonari Uesugi
- Institute for Chemical Research and WPI-iCeMS, Kyoto University, Uji, Kyoto, 611-0011, Japan
| | - Toshiaki Sunazuka
- Omura Satoshi Memorial Institute and Graduate School of Infection Control Sciences, Kitasato University, Minato-ku, Tokyo, 108-8641, Japan
| | - Kazuya Kikuchi
- Department of Applied Chemistry, Graduate School of Engineering, Osaka University, Suita, Osaka, 565-0871, Japan
- Immunology Frontier Research Centre, Osaka University, Suita, Osaka, 565-0871, Japan
| | - Hideaki Kakeya
- Division of Medicinal Frontier Sciences, Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, Kyoto, 606-8501, Japan
| | - Yasubumi Sakakibara
- Department of Biosciences and Informatics, Keio University, Yokohama, Kanagawa, 223-8522, Japan.
- Department of Data Science, Kitasato University School of Frontier Engineering, Sagamihara, Kanagawa, 252-0373, Japan.
| |
Collapse
|
82
|
Yoo P, Bhowmik D, Mehta K, Zhang P, Liu F, Lupo Pasini M, Irle S. Deep learning workflow for the inverse design of molecules with specific optoelectronic properties. Sci Rep 2023; 13:20031. [PMID: 37973879 PMCID: PMC10654498 DOI: 10.1038/s41598-023-45385-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2023] [Accepted: 10/19/2023] [Indexed: 11/19/2023] Open
Abstract
The inverse design of novel molecules with a desirable optoelectronic property requires consideration of the vast chemical spaces associated with varying chemical composition and molecular size. First principles-based property predictions have become increasingly helpful for assisting the selection of promising candidate chemical species for subsequent experimental validation. However, a brute-force computational screening of the entire chemical space is decidedly impossible. To alleviate the computational burden and accelerate rational molecular design, we here present an iterative deep learning workflow that combines (i) the density-functional tight-binding method for dynamic generation of property training data, (ii) a graph convolutional neural network surrogate model for rapid and reliable predictions of chemical and physical properties, and (iii) a masked language model. As proof of principle, we employ our workflow in the iterative generation of novel molecules with a target energy gap between the highest occupied molecular orbital (HOMO) and the lowest unoccupied molecular orbital (LUMO).
Collapse
Affiliation(s)
- Pilsun Yoo
- Computational Sciences and Engineering Division, Oak Ridge National Laboratory, 1 Bethel Valley Road, Oak Ridge, TN, 37831, USA.
| | - Debsindhu Bhowmik
- Computational Sciences and Engineering Division, Oak Ridge National Laboratory, 1 Bethel Valley Road, Oak Ridge, TN, 37831, USA
| | - Kshitij Mehta
- Computer Science and Mathematics Division, Oak Ridge National Laboratory, 1 Bethel Valley Road, Oak Ridge, TN, 37831, USA
| | - Pei Zhang
- Computational Sciences and Engineering Division, Oak Ridge National Laboratory, 1 Bethel Valley Road, Oak Ridge, TN, 37831, USA
| | - Frank Liu
- Computer Science and Mathematics Division, Oak Ridge National Laboratory, 1 Bethel Valley Road, Oak Ridge, TN, 37831, USA
| | - Massimiliano Lupo Pasini
- Computational Sciences and Engineering Division, Oak Ridge National Laboratory, 1 Bethel Valley Road, Oak Ridge, TN, 37831, USA
| | - Stephan Irle
- Computational Sciences and Engineering Division, Oak Ridge National Laboratory, 1 Bethel Valley Road, Oak Ridge, TN, 37831, USA.
| |
Collapse
|
83
|
Toniato A, Vaucher AC, Lehmann MM, Luksch T, Schwaller P, Stenta M, Laino T. Fast Customization of Chemical Language Models to Out-of-Distribution Data Sets. CHEMISTRY OF MATERIALS : A PUBLICATION OF THE AMERICAN CHEMICAL SOCIETY 2023; 35:8806-8815. [PMID: 38027545 PMCID: PMC10653079 DOI: 10.1021/acs.chemmater.3c01406] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 06/06/2023] [Revised: 10/09/2023] [Accepted: 10/09/2023] [Indexed: 12/01/2023]
Abstract
The world is on the verge of a new industrial revolution, and language models are poised to play a pivotal role in this transformative era. Their ability to offer intelligent insights and forecasts has made them a valuable asset for businesses seeking a competitive advantage. The chemical industry, in particular, can benefit significantly from harnessing their power. Since 2016 already, language models have been applied to tasks such as predicting reaction outcomes or retrosynthetic routes. While such models have demonstrated impressive abilities, the lack of publicly available data sets with universal coverage is often the limiting factor for achieving even higher accuracies. This makes it imperative for organizations to incorporate proprietary data sets into their model training processes to improve their performance. So far, however, these data sets frequently remain untapped as there are no established criteria for model customization. In this work, we report a successful methodology for retraining language models on reaction outcome prediction and single-step retrosynthesis tasks, using proprietary, nonpublic data sets. We report a considerable boost in accuracy by combining patent and proprietary data in a multidomain learning formulation. This exercise, inspired by a real-world use case, enables us to formulate guidelines that can be adopted in different corporate settings to customize chemical language models easily.
Collapse
Affiliation(s)
- Alessandra Toniato
- IBM
Research Europe, Rüschlikon 8803, Switzerland
- National
Center for Competence in Research-Catalysis (NCCR-Catalysis), 8093 Zürich, Switzerland
| | - Alain C. Vaucher
- IBM
Research Europe, Rüschlikon 8803, Switzerland
- National
Center for Competence in Research-Catalysis (NCCR-Catalysis), 8093 Zürich, Switzerland
| | | | | | - Philippe Schwaller
- IBM
Research Europe, Rüschlikon 8803, Switzerland
- National
Center for Competence in Research-Catalysis (NCCR-Catalysis), 8093 Zürich, Switzerland
| | - Marco Stenta
- Syngenta
Crop Protection AG, Stein 4332, Switzerland
| | - Teodoro Laino
- IBM
Research Europe, Rüschlikon 8803, Switzerland
- National
Center for Competence in Research-Catalysis (NCCR-Catalysis), 8093 Zürich, Switzerland
| |
Collapse
|
84
|
Yu L, He X, Fang X, Liu L, Liu J. Deep Learning with Geometry-Enhanced Molecular Representation for Augmentation of Large-Scale Docking-Based Virtual Screening. J Chem Inf Model 2023; 63:6501-6514. [PMID: 37882338 DOI: 10.1021/acs.jcim.3c01371] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2023]
Abstract
Structure-based virtual screening has been a crucial tool in drug discovery for decades. However, as the chemical space expands, the existing structure-based virtual screening techniques based on molecular docking and scoring struggle to handle billion-entry ultralarge libraries due to the high computational cost. To address this challenge, people have resorted to machine learning techniques to enhance structure-based virtual screening for efficiently exploring the vast chemical space. In those cases, compounds are usually treated as sequential strings or two-dimensional topology graphs, limiting their ability to incorporate three-dimensional structural information for downstream tasks. We herein propose a novel deep learning protocol, GEM-Screen, which utilizes the geometry-enhanced molecular representation of the compounds docking to a specific target and is trained on docking scores of a small fraction of a library through an active learning strategy to approximate the docking outcome for yet nontraining entries. This protocol is applied to virtual screening campaigns against the AmpC and D4 targets, demonstrating that GEM-Screen enriches more than 90% of the hit scaffolds for AmpC in the top 4% of model predictions and more than 80% of the hit scaffolds for D4 in the same top-ranking size of library. GEM-Screen can be used in conjunction with traditional docking programs for docking of only the top-ranked compounds to avoid the exhaustive docking of the whole library, thus allowing for discovering top-scoring compounds from billion-entry libraries in a rapid yet accurate fashion.
Collapse
Affiliation(s)
- Lan Yu
- School of Science, China Pharmaceutical University, Nanjing 210009, China
| | - Xiao He
- Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, Shanghai Frontiers Science Center of Molecule Intelligent Syntheses, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai 200062, China
- New York University-East China Normal University Center for Computational Chemistry, New York University Shanghai, Shanghai 200062, China
| | - Xiaomin Fang
- Baidu International Technology (Shenzhen) Co., Ltd., Shenzhen 518063, China
| | - Lihang Liu
- Baidu International Technology (Shenzhen) Co., Ltd., Shenzhen 518063, China
| | - Jinfeng Liu
- School of Science, China Pharmaceutical University, Nanjing 210009, China
- School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing 210009, China
| |
Collapse
|
85
|
Zou J, Zhao L, Shi S. Generation of focused drug molecule library using recurrent neural network. J Mol Model 2023; 29:361. [PMID: 37932607 DOI: 10.1007/s00894-023-05772-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2023] [Accepted: 10/26/2023] [Indexed: 11/08/2023]
Abstract
CONTEXT With the wide application of deep learning in drug research and development, de novo molecular design methods based on recurrent neural network (RNN) have strong advantages in drug molecule generation. The RNN model can be used to learn the internal chemical structure of molecules, which is similar to a natural language processing task. Although techniques for generating target-specific molecular libraries based on RNN models are mature, research related to drug design and screening continues around the clock. Research based on de novo drug design methods to generate larger quantities of valid compounds is necessary. METHODS In this study, a molecular generation model based on RNN was designed, which abandoned the traditional way of stacked RNN and introduced the Nested long short-term memory network structure. To enrich the library of focused molecules for specific targets, we fine-tuned the model using active molecules from novel coronavirus pneumonia and screened the molecules using machine learning models. Following rigorous screening, the selected molecules underwent molecular docking with the SARS-CoV-2 M-pro receptor using AutoDock2.4 to identify the top 3 potential inhibitors. Subsequently, 100-ns molecular dynamics simulations were conducted using Amber22. Molecule parameterization involved the GAFF2 force field, while the proteins were modeled using the ff19SB force field, with solvation facilitated by a truncated octahedral TIP3P solvent environment. Upon completion of molecular dynamics simulations, stability of ligand-protein complexes was assessed by analysis of RMSD, H-bonds, and MM-GBSA. Reasonable results prove that the model can complete the task of de novo drug design and has the potential to be ideal drug molecules.
Collapse
Affiliation(s)
- Jinping Zou
- Department of Mathematics, School of Mathematics and Computer Sciences, Nanchang University, Nanchang, 330031, China
- Institute of Mathematics and Interdisciplinary Sciences, Nanchang University, Nanchang, 330031, China
| | - Long Zhao
- Department of Mathematics, School of Mathematics and Computer Sciences, Nanchang University, Nanchang, 330031, China
- Institute of Mathematics and Interdisciplinary Sciences, Nanchang University, Nanchang, 330031, China
| | - Shaoping Shi
- Department of Mathematics, School of Mathematics and Computer Sciences, Nanchang University, Nanchang, 330031, China.
- Institute of Mathematics and Interdisciplinary Sciences, Nanchang University, Nanchang, 330031, China.
| |
Collapse
|
86
|
Wang Q, Wei Z, Hu X, Wang Z, Dong Y, Liu H. Molecular generation strategy and optimization based on A2C reinforcement learning in de novo drug design. Bioinformatics 2023; 39:btad693. [PMID: 37971970 PMCID: PMC10689670 DOI: 10.1093/bioinformatics/btad693] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2023] [Revised: 10/08/2023] [Accepted: 11/15/2023] [Indexed: 11/19/2023] Open
Abstract
MOTIVATION In the field of pharmacochemistry, it is a time-consuming and expensive process for the new drug development. The existing drug design methods face a significant challenge in terms of generation efficiency and quality. RESULTS In this paper, we proposed a novel molecular generation strategy and optimization based on A2C reinforcement learning. In molecular generation strategy, we adopted transformer-DNN to retain the scaffolds advantages, while accounting for the generated molecules' similarity and internal diversity by dynamic parameter adjustment, further improving the overall quality of molecule generation. In molecular optimization, we introduced heterogeneous parallel supercomputing for large-scale molecular docking based on message passing interface communication technology to rapidly obtain bioactive information, thereby enhancing the efficiency of drug design. Experiments show that our model can generate high-quality molecules with multi-objective properties at a high generation efficiency, with effectiveness and novelty close to 100%. Moreover, we used our method to assist shandong university school of pharmacy to find several candidate drugs molecules of anti-PEDV. AVAILABILITY AND IMPLEMENTATION The datasets involved in this method and the source code are freely available to academic users at https://github.com/wq-sunshine/MomdTDSRL.git.
Collapse
Affiliation(s)
- Qian Wang
- College of Computer Science and Technology, Ocean University of China, Qingdao, Shandong 266100, China
| | - Zhiqiang Wei
- College of Computer Science and Technology, Ocean University of China, Qingdao, Shandong 266100, China
| | - Xiaotong Hu
- College of Computer Science and Technology, Ocean University of China, Qingdao, Shandong 266100, China
| | - Zhuoya Wang
- Center for High Performance Computing and System Simulation, National Laboratory for Marine Science and Technology, Qingdao, Shandong 266237, China
| | - Yujie Dong
- Marine Big Data Center of Institute for Advanced Ocean Study, Ocean University of China, Qingdao, Shandong 266100, China
| | - Hao Liu
- College of Computer Science and Technology, Ocean University of China, Qingdao, Shandong 266100, China
| |
Collapse
|
87
|
Ilnicka A, Schneider G. Designing molecules with autoencoder networks. NATURE COMPUTATIONAL SCIENCE 2023; 3:922-933. [PMID: 38177601 DOI: 10.1038/s43588-023-00548-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/01/2023] [Accepted: 10/03/2023] [Indexed: 01/06/2024]
Abstract
Autoencoders are versatile tools in molecular informatics. These unsupervised neural networks serve diverse tasks such as data-driven molecular representation and constructive molecular design. This Review explores their algorithmic foundations and applications in drug discovery, highlighting the most active areas of development and the contributions autoencoder networks have made in advancing this field. We also explore the challenges and prospects concerning the utilization of autoencoders and the various adaptations of this neural network architecture in molecular design.
Collapse
Affiliation(s)
- Agnieszka Ilnicka
- Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, Switzerland
| | - Gisbert Schneider
- Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, Switzerland.
| |
Collapse
|
88
|
Mullowney MW, Duncan KR, Elsayed SS, Garg N, van der Hooft JJJ, Martin NI, Meijer D, Terlouw BR, Biermann F, Blin K, Durairaj J, Gorostiola González M, Helfrich EJN, Huber F, Leopold-Messer S, Rajan K, de Rond T, van Santen JA, Sorokina M, Balunas MJ, Beniddir MA, van Bergeijk DA, Carroll LM, Clark CM, Clevert DA, Dejong CA, Du C, Ferrinho S, Grisoni F, Hofstetter A, Jespers W, Kalinina OV, Kautsar SA, Kim H, Leao TF, Masschelein J, Rees ER, Reher R, Reker D, Schwaller P, Segler M, Skinnider MA, Walker AS, Willighagen EL, Zdrazil B, Ziemert N, Goss RJM, Guyomard P, Volkamer A, Gerwick WH, Kim HU, Müller R, van Wezel GP, van Westen GJP, Hirsch AKH, Linington RG, Robinson SL, Medema MH. Artificial intelligence for natural product drug discovery. Nat Rev Drug Discov 2023; 22:895-916. [PMID: 37697042 DOI: 10.1038/s41573-023-00774-7] [Citation(s) in RCA: 33] [Impact Index Per Article: 33.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/20/2023] [Indexed: 09/13/2023]
Abstract
Developments in computational omics technologies have provided new means to access the hidden diversity of natural products, unearthing new potential for drug discovery. In parallel, artificial intelligence approaches such as machine learning have led to exciting developments in the computational drug design field, facilitating biological activity prediction and de novo drug design for molecular targets of interest. Here, we describe current and future synergies between these developments to effectively identify drug candidates from the plethora of molecules produced by nature. We also discuss how to address key challenges in realizing the potential of these synergies, such as the need for high-quality datasets to train deep learning algorithms and appropriate strategies for algorithm validation.
Collapse
Affiliation(s)
| | - Katherine R Duncan
- Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK
| | - Somayah S Elsayed
- Department of Molecular Biotechnology, Institute of Biology, Leiden University, Leiden, The Netherlands
| | - Neha Garg
- School of Chemistry and Biochemistry, Center for Microbial Dynamics and Infection, Georgia Institute of Technology, Atlanta, GA, USA
| | - Justin J J van der Hooft
- Bioinformatics Group, Wageningen University, Wageningen, The Netherlands
- Department of Biochemistry, University of Johannesburg, Johannesburg, South Africa
| | - Nathaniel I Martin
- Biological Chemistry Group, Institute of Biology, Leiden University, Leiden, The Netherlands
| | - David Meijer
- Bioinformatics Group, Wageningen University, Wageningen, The Netherlands
| | - Barbara R Terlouw
- Bioinformatics Group, Wageningen University, Wageningen, The Netherlands
| | - Friederike Biermann
- Bioinformatics Group, Wageningen University, Wageningen, The Netherlands
- Institute of Molecular Bio Science, Goethe-University Frankfurt, Frankfurt am Main, Germany
- LOEWE Center for Translational Biodiversity Genomics (TBG), Frankfurt am Main, Germany
| | - Kai Blin
- The Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark, Kongens Lyngby, Denmark
| | | | - Marina Gorostiola González
- Drug Discovery and Safety, Leiden Academic Centre for Drug Research, Leiden, The Netherlands
- ONCODE institute, Leiden, The Netherlands
| | - Eric J N Helfrich
- Institute of Molecular Bio Science, Goethe-University Frankfurt, Frankfurt am Main, Germany
- LOEWE Center for Translational Biodiversity Genomics (TBG), Frankfurt am Main, Germany
| | - Florian Huber
- Center for Digitalization and Digitality, Hochschule Düsseldorf, Düsseldorf, Germany
| | - Stefan Leopold-Messer
- Institut für Mikrobiologie, Eidgenössische Technische Hochschule (ETH) Zürich, Zürich, Switzerland
| | - Kohulan Rajan
- Institute for Inorganic and Analytical Chemistry, Friedrich-Schiller-University Jena, Jena, Germany
| | - Tristan de Rond
- School of Chemical Sciences, University of Auckland, Auckland, New Zealand
| | - Jeffrey A van Santen
- Department of Chemistry, Simon Fraser University, Burnaby, British Columbia, Canada
| | - Maria Sorokina
- Institute for Inorganic and Analytical Chemistry, Friedrich-Schiller University, Jena, Germany
- Pharmaceuticals R&D, Bayer AG, Berlin, Germany
| | - Marcy J Balunas
- Department of Microbiology and Immunology, University of Michigan, Ann Arbor, MI, USA
- Department of Medicinal Chemistry, University of Michigan, Ann Arbor, MI, USA
| | - Mehdi A Beniddir
- Équipe "Chimie des Substances Naturelles", Université Paris-Saclay, CNRS, BioCIS, Orsay, France
| | - Doris A van Bergeijk
- Department of Molecular Biotechnology, Institute of Biology, Leiden University, Leiden, The Netherlands
| | - Laura M Carroll
- Structural and Computational Biology Unit, EMBL, Heidelberg, Germany
| | - Chase M Clark
- Division of Pharmaceutical Sciences, School of Pharmacy, University of Wisconsin-Madison, Madison, WI, USA
| | | | | | - Chao Du
- Department of Molecular Biotechnology, Institute of Biology, Leiden University, Leiden, The Netherlands
| | | | - Francesca Grisoni
- Institute for Complex Molecular Systems, Department of Biomedical Engineering, Eindhoven University of Technology, Eindhoven, The Netherlands
- Centre for Living Technologies, Alliance TU/e, WUR, UU, UMC Utrecht, Utrecht, The Netherlands
| | | | - Willem Jespers
- Drug Discovery and Safety, Leiden Academic Centre for Drug Research, Leiden, The Netherlands
| | - Olga V Kalinina
- Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Centre for Infection Research (HZI), Saarbrücken, Germany
- Drug Bioinformatics, Medical Faculty, Saarland University, Homburg, Germany
- Center for Bioinformatics, Saarland University, Saarbrücken, Germany
| | | | - Hyunwoo Kim
- College of Pharmacy and Integrated Research Institute for Drug Development, Dongguk University Seoul, Goyang-si, Republic of Korea
| | - Tiago F Leao
- Center for Nuclear Energy in Agriculture, University of São Paulo, Piracicaba, Brazil
| | - Joleen Masschelein
- Center for Microbiology, VIB-KU Leuven, Heverlee, Belgium
- Department of Biology, KU Leuven, Heverlee, Belgium
| | - Evan R Rees
- Division of Pharmaceutical Sciences, School of Pharmacy, University of Wisconsin-Madison, Madison, WI, USA
| | - Raphael Reher
- Institute of Pharmaceutical Biology and Biotechnology, University of Marburg, Marburg, Germany
- Institute of Pharmacy, Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany
| | - Daniel Reker
- Department of Biomedical Engineering, Duke University, Durham, NC, USA
- Duke Microbiome Center, Duke University, Durham, NC, USA
| | - Philippe Schwaller
- Laboratory of Artificial Chemical Intelligence, Institut des Sciences et Ingénierie Chimiques, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
| | | | - Michael A Skinnider
- Adapsyn Bioscience, Hamilton, Ontario, Canada
- Michael Smith Laboratories, University of British Columbia, Vancouver, British Columbia, Canada
| | - Allison S Walker
- Department of Chemistry, Vanderbilt University, Nashville, TN, USA
- Department of Biological Sciences, Vanderbilt University, Nashville, TN, USA
| | - Egon L Willighagen
- Department of Bioinformatics - BiGCaT, NUTRIM, Maastricht University, Maastricht, The Netherlands
| | - Barbara Zdrazil
- European Bioinformatics Institute (EMBL-EBI), Wellcome Genome Campus, Cambridgeshire, UK
| | - Nadine Ziemert
- Interfaculty Institute for Microbiology and Infection Medicine Tuebingen (IMIT), Institute for Bioinformatics and Medical Informatics (IBMI), University of Tuebingen, Tuebingen, Germany
| | | | - Pierre Guyomard
- Bonsai team, CRIStAL - Centre de Recherche en Informatique Signal et Automatique de Lille, Université de Lille, Villeneuve d'Ascq Cedex, France
| | - Andrea Volkamer
- Center for Bioinformatics, Saarland University, Saarbrücken, Germany
- In silico Toxicology and Structural Bioinformatics, Institute of Physiology, Charité - Universitätsmedizin Berlin, Berlin, Germany
| | - William H Gerwick
- Scripps Institution of Oceanography, University of California San Diego, La Jolla, CA, USA
| | - Hyun Uk Kim
- Department of Chemical and Biomolecular Engineering, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, Korea
| | - Rolf Müller
- Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Centre for Infection Research (HZI), Saarbrücken, Germany
- Department of Pharmacy, Saarland University, Saarbrücken, Germany
- German Center for infection research (DZIF), Braunschweig, Germany
- Helmholtz International Lab for Anti-Infectives, Saarbrücken, Germany
| | - Gilles P van Wezel
- Department of Molecular Biotechnology, Institute of Biology, Leiden University, Leiden, The Netherlands
- Netherlands Institute of Ecology, NIOO-KNAW, Wageningen, The Netherlands
| | - Gerard J P van Westen
- Drug Discovery and Safety, Leiden Academic Centre for Drug Research, Leiden, The Netherlands.
| | - Anna K H Hirsch
- Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Centre for Infection Research (HZI), Saarbrücken, Germany.
- Department of Pharmacy, Saarland University, Saarbrücken, Germany.
- German Center for infection research (DZIF), Braunschweig, Germany.
- Helmholtz International Lab for Anti-Infectives, Saarbrücken, Germany.
| | - Roger G Linington
- Department of Chemistry, Simon Fraser University, Burnaby, British Columbia, Canada.
| | - Serina L Robinson
- Department of Environmental Microbiology, Eawag: Swiss Federal Institute for Aquatic Science and Technology, Dübendorf, Switzerland.
| | - Marnix H Medema
- Bioinformatics Group, Wageningen University, Wageningen, The Netherlands.
- Institute of Biology, Leiden University, Leiden, The Netherlands.
| |
Collapse
|
89
|
Kumar S, Roy V. Repurposing Drugs: An Empowering Approach to Drug Discovery and Development. Drug Res (Stuttg) 2023; 73:481-490. [PMID: 37478892 DOI: 10.1055/a-2095-0826] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 07/23/2023]
Abstract
Drug discovery and development is a time-consuming and costly procedure that necessitates a substantial effort. Drug repurposing has been suggested as a method for developing medicines that takes less time than developing brand new medications and will be less expensive. Also known as drug repositioning or re-profiling, this strategy has been in use from the time of serendipitous drug discoveries to the modern computer aided drug designing and use of computational chemistry. In the light of the COVID-19 pandemic too, drug repurposing emerged as a ray of hope in the dearth of available medicines. Data availability by electronic recording, libraries, and improvements in computational techniques offer a vital substrate for systemic evaluation of repurposing candidates. In the not-too-distant future, it could be possible to create a global research archive for us to access, thus accelerating the process of drug development and repurposing. This review aims to present the evolution, benefits and drawbacks including current approaches, key players and the legal and regulatory hurdles in the field of drug repurposing. The vast quantities of available data secured in multiple drug databases, assisting in drug repurposing is also discussed.
Collapse
Affiliation(s)
- Sahil Kumar
- Pharmacology, ESIC Dental College and Hospital, New Delhi, India
| | - Vandana Roy
- Pharmacology, Maulana Azad Medical College, New Delhi, India
| |
Collapse
|
90
|
Choung OH, Vianello R, Segler M, Stiefl N, Jiménez-Luna J. Extracting medicinal chemistry intuition via preference machine learning. Nat Commun 2023; 14:6651. [PMID: 37907461 PMCID: PMC10618272 DOI: 10.1038/s41467-023-42242-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2023] [Accepted: 09/21/2023] [Indexed: 11/02/2023] Open
Abstract
The lead optimization process in drug discovery campaigns is an arduous endeavour where the input of many medicinal chemists is weighed in order to reach a desired molecular property profile. Building the expertise to successfully drive such projects collaboratively is a very time-consuming process that typically spans many years within a chemist's career. In this work we aim to replicate this process by applying artificial intelligence learning-to-rank techniques on feedback that was obtained from 35 chemists at Novartis over the course of several months. We exemplify the usefulness of the learned proxies in routine tasks such as compound prioritization, motif rationalization, and biased de novo drug design. Annotated response data is provided, and developed models and code made available through a permissive open-source license.
Collapse
Affiliation(s)
- Oh-Hyeon Choung
- Novartis Institutes for Biomedical Research, 4002, Basel, Switzerland
| | - Riccardo Vianello
- Novartis Institutes for Biomedical Research, 4002, Basel, Switzerland
| | - Marwin Segler
- Microsoft Research AI4Science, CB1 2FB, Cambridge, UK
| | - Nikolaus Stiefl
- Novartis Institutes for Biomedical Research, 4002, Basel, Switzerland.
| | | |
Collapse
|
91
|
Wu Y, Wei H, Zhu Q, Luo R. Grid-Robust Efficient Neural Interface Model for Universal Molecule Surface Construction from Point Clouds. J Phys Chem Lett 2023; 14:9034-9041. [PMID: 37782231 PMCID: PMC10577766 DOI: 10.1021/acs.jpclett.3c02176] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2023] [Accepted: 09/26/2023] [Indexed: 10/03/2023]
Abstract
Molecular surfaces play a pivotal role in elucidating the properties and functions of biological complexes. While various surfaces have been proposed for specific scenarios, their widespread adoption faces challenges due to limited efficiency stemming from hand-crafted modeling designs. In this work, we proposed a general framework that incorporates both the point cloud concept and neural networks. The use of matrix multiplication in this framework enables efficient implementation across diverse platforms and libraries. We applied this framework to develop the GENIUSES (Grid-robust Efficient Neural Interface for Universal Solvent-Excluded Surface) model for constructing SES. GENIUSES demonstrates high accuracy and efficiency across data sets with varying conformations and complexities. Compared to the classical implementation of SES in the AMBER software package, our framework achieved a 26-fold speedup while retaining ∼95% accuracy when ported to the GPU platform using CUDA. Greater speedups can be obtained in large-scale systems. Importantly, our model exhibits robustness against variations in the grid spacing. We have integrated this infrastructure into AMBER to enhance accessibility for research in drug screening and related fields, where efficiency is of paramount importance.
Collapse
Affiliation(s)
- Yongxian Wu
- Departments
of Chemical and Biomolecular Engineering, Molecular Biology and Biochemistry,
Materials Science and Engineering, and Biomedical Engineering, University of California, Irvine, California 92697, United States
| | - Haixin Wei
- Department
of Chemistry and Biochemistry, University
of California, San Diego, California 92093, United States
| | - Qiang Zhu
- Departments
of Chemical and Biomolecular Engineering, Molecular Biology and Biochemistry,
Materials Science and Engineering, and Biomedical Engineering, University of California, Irvine, California 92697, United States
| | - Ray Luo
- Departments
of Chemical and Biomolecular Engineering, Molecular Biology and Biochemistry,
Materials Science and Engineering, and Biomedical Engineering, University of California, Irvine, California 92697, United States
| |
Collapse
|
92
|
Erikawa D, Yasuo N, Suzuki T, Nakamura S, Sekijima M. Gargoyles: An Open Source Graph-Based Molecular Optimization Method Based on Deep Reinforcement Learning. ACS OMEGA 2023; 8:37431-37441. [PMID: 37841174 PMCID: PMC10568706 DOI: 10.1021/acsomega.3c05430] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 07/26/2023] [Accepted: 09/13/2023] [Indexed: 10/17/2023]
Abstract
Automatic optimization methods for compounds in the vast compound space are important for drug discovery and material design. Several machine learning-based molecular generative models for drug discovery have been proposed, but most of these methods generate compounds from scratch and are not suitable for exploring and optimizing user-defined compounds. In this study, we developed a compound optimization method based on molecular graphs using deep reinforcement learning. This method searches for compounds on a fragment-by-fragment basis and at high density by generating fragments to be added atom by atom. Experimental results confirmed that the quantum electrodynamics (QED), the optimization target set in this study, was enhanced by searching around the starting compound. As a use case, we successfully enhanced the activity of a compound by targeting dopamine receptor D2 (DRD2). This means that the generated compounds are not structurally dissimilar from the starting compounds, as well as increasing their activity, indicating that this method is suitable for optimizing molecules from a given compound. The source code is available at https://github.com/sekijima-lab/GARGOYLES.
Collapse
Affiliation(s)
- Daiki Erikawa
- Department
of Computer Science, Tokyo Institute of
Technology, 4259-J3-23, Nagatsuta-cho, Midori-ku, Yokohama 226-8501, Japan
| | - Nobuaki Yasuo
- Academy
for Convergence of Materials and Informatics (TAC-MI), Tokyo Institute of Technology, S6-23, Ookayama, Meguro-ku, Tokyo 152-8550, Japan
| | - Takamasa Suzuki
- Department
of Computer Science, Tokyo Institute of
Technology, 4259-J3-23, Nagatsuta-cho, Midori-ku, Yokohama 226-8501, Japan
| | - Shogo Nakamura
- Department
of Life Science and Technology, Tokyo Institute
of Technology, 4259-J3-23, Nagatsuta-cho, Midori-ku, Yokohama 226-8501, Japan
| | - Masakazu Sekijima
- Department
of Computer Science, Tokyo Institute of
Technology, 4259-J3-23, Nagatsuta-cho, Midori-ku, Yokohama 226-8501, Japan
| |
Collapse
|
93
|
Zhu H, Zhou R, Cao D, Tang J, Li M. A pharmacophore-guided deep learning approach for bioactive molecular generation. Nat Commun 2023; 14:6234. [PMID: 37803000 PMCID: PMC10558534 DOI: 10.1038/s41467-023-41454-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2022] [Accepted: 08/30/2023] [Indexed: 10/08/2023] Open
Abstract
The rational design of novel molecules with the desired bioactivity is a critical but challenging task in drug discovery, especially when treating a novel target family or understudied targets. We propose a Pharmacophore-Guided deep learning approach for bioactive Molecule Generation (PGMG). Through the guidance of pharmacophore, PGMG provides a flexible strategy for generating bioactive molecules. PGMG uses a graph neural network to encode spatially distributed chemical features and a transformer decoder to generate molecules. A latent variable is introduced to solve the many-to-many mapping between pharmacophores and molecules to improve the diversity of the generated molecules. Compared to existing methods, PGMG generates molecules with strong docking affinities and high scores of validity, uniqueness, and novelty. In the case studies, we use PGMG in a ligand-based and structure-based drug de novo design. Overall, the flexibility and effectiveness make PGMG a useful tool to accelerate the drug discovery process.
Collapse
Affiliation(s)
- Huimin Zhu
- School of Computer Science and Engineering, Central South University, Changsha, 410083, China
| | - Renyi Zhou
- School of Computer Science and Engineering, Central South University, Changsha, 410083, China
| | - Dongsheng Cao
- Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, 410008, China
| | - Jing Tang
- Research Program in Systems Oncology, Faculty of Medicine, University of Helsinki, Helsinki, 00290, Finland
- Department of Biochemistry and Developmental Biology, Faculty of Medicine, University of Helsinki, Helsinki, 00290, Finland
| | - Min Li
- School of Computer Science and Engineering, Central South University, Changsha, 410083, China.
| |
Collapse
|
94
|
Riedl M, Mukherjee S, Gauthier M. Descriptor-Free Deep Learning QSAR Model for the Fraction Unbound in Human Plasma. Mol Pharm 2023; 20:4984-4993. [PMID: 37656906 DOI: 10.1021/acs.molpharmaceut.3c00129] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/03/2023]
Abstract
Chemical-specific parameters are either measured in vitro or estimated using quantitative structure-activity relationship (QSAR) models. The existing body of QSAR work relies on extracting a set of descriptors or fingerprints, subset selection, and training a machine learning model. In this work, we used a state-of-the-art natural language processing model, Bidirectional Encoder Representations from Transformers, which allowed us to circumvent the need for calculation of these chemical descriptors. In this approach, simplified molecular-input line-entry system (SMILES) strings were embedded in a high-dimensional space using a two-stage training approach. The model was first pre-trained on a masked SMILES token task and then fine-tuned on a QSAR prediction task. The pre-training task learned meaningful high-dimensional embeddings based upon the relationships between the chemical tokens in the SMILES strings derived from the "in-stock" portion of the ZINC 15 dataset─a large dataset of commercially available chemicals. The fine-tuning task then perturbed the pre-trained embeddings to facilitate prediction of a specific QSAR endpoint of interest. The power of this model stems from the ability to reuse the pre-trained model for multiple different fine-tuning tasks, reducing the computational burden of developing multiple models for different endpoints. We used our framework to develop a predictive model for fraction unbound in human plasma (fu,p). This approach is flexible, requires minimum domain expertise, and can be generalized for other parameters of interest for rapid and accurate estimation of absorption, distribution, metabolism, excretion, and toxicity.
Collapse
|
95
|
Sivangi KB, Amilpur S, Dasari CM. ReGen-DTI: A novel generative drug target interaction model for predicting potential drug candidates against SARS-COV2. Comput Biol Chem 2023; 106:107927. [PMID: 37499436 DOI: 10.1016/j.compbiolchem.2023.107927] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2023] [Revised: 07/12/2023] [Accepted: 07/13/2023] [Indexed: 07/29/2023]
Abstract
Covid-19 has caused massive numbers of infections and fatalities globally. In response, there has been a large-scale experimental and computational research effort to study and develop drugs. Towards this, Deep learning techniques are used for the generation of potential novel drug candidates that are proven to be effective against exploring large molecular search spaces. Recent advances in reinforcement learning in conjunction with generative techniques has proven to be a promising field in the area of drug discovery. In this regard, we propose a generative drug discovery approach using reinforcement techniques for sampling novel molecules that bind to the main protease of SARS-COV2. The generative method reported significant validity scores for the generated novel molecules and captured the underlying features of the training molecules. Further, the model is fine-tuned on existing re-purposed molecules which are active towards specific target proteins based on similarity metrics. Upon fine tuning the model generated 92.71% valid, 93.55% unique, and 100% novel molecules. Unlike previous methods which are dependent on docking procedures, we proposed a deep learning based novel drug target interaction (DTI) model to find the binding affinity between candidate molecules and target protease sequence. Finally, the binding affinity of the generated molecules is predicted against the 3CLPro main protease by using the proposed DTI model. Most of the generated molecules have shown binding affinity scores <100 nM (lower the better), which are significantly better compared to the existing commercial drugs including Remdesevir.
Collapse
Affiliation(s)
- Kaushik Bhargav Sivangi
- Indian Institute of Information Technology, Sri City, Chittoor, 517646, Andhra Pradesh, India
| | - Santhosh Amilpur
- Indian Institute of Information Technology, Sri City, Chittoor, 517646, Andhra Pradesh, India
| | - Chandra Mohan Dasari
- Indian Institute of Information Technology, Sri City, Chittoor, 517646, Andhra Pradesh, India.
| |
Collapse
|
96
|
Stanley M, Segler M. Fake it until you make it? Generative de novo design and virtual screening of synthesizable molecules. Curr Opin Struct Biol 2023; 82:102658. [PMID: 37473637 DOI: 10.1016/j.sbi.2023.102658] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2023] [Revised: 06/21/2023] [Accepted: 06/22/2023] [Indexed: 07/22/2023]
Abstract
Computational techniques, including virtual screening, de novo design, and generative models, play an increasing role in expediting DMTA cycles for modern molecular discovery. However, computationally proposed molecules must be synthetically feasible for laboratory testing. In this perspective, we offer a succinct introduction to the subject, and showcase typical workflows to integrate synthesis planning, synthesizability scoring, and molecule generation. Finally, we address limitations and opportunities for future research.
Collapse
Affiliation(s)
- Megan Stanley
- Microsoft Research AI4Science, UK. https://twitter.com/@megjanestanley
| | | |
Collapse
|
97
|
Haroon S, C A H, A S J. Generative Pre-trained Transformer (GPT) based model with relative attention for de novo drug design. Comput Biol Chem 2023; 106:107911. [PMID: 37450999 DOI: 10.1016/j.compbiolchem.2023.107911] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2023] [Revised: 06/24/2023] [Accepted: 06/28/2023] [Indexed: 07/18/2023]
Abstract
De novo drug design refers to the process of designing new drug molecules from scratch using computational methods. In contrast to other computational methods that primarily focus on modifying existing molecules, designing from scratch enables the exploration of new chemical space and the potential discovery of novel molecules with enhanced properties. In this research, we proposed a model that utilizes Generative Pre-trained Transformer (GPT) architecture and relative attention for de novo drug design. GPT is a language model that utilizes transformer architecture to predict the next word or token in a given sequence. Representation of molecules using SMILES notation has enabled the use of next-token prediction techniques in de novo drug design. GPT uses attention mechanisms to capture the dependencies and relationships between different tokens in a sequence and allows the model to focus on the most important information when processing the input. Relative attention is a variant of the attention mechanism, which allows the model to capture the relative distances and relationships between tokens in the input sequence. In the standard attention mechanism, positional information is typically encoded using fixed-position embeddings. In relative attention, positional information is supplied dynamically during attention calculation by incorporating relative positional encodings, enabling the model to quickly learn the syntax of new unseen tokens. Relative attention enables the GPT model to better understand the relative positions of tokens in the sequence, which can be particularly useful when dealing with limited dataset sizes or generating target-specific drugs. The proposed model was trained on benchmark datasets, and performance was compared with other generative models. We show that relative attention and transfer learning could enable the GPT model to generate molecules with improved validity, uniqueness, and novelty in the context of de novo drug design. To illustrate the effectiveness of relative attention, the model was trained using transfer learning on three target-specific datasets, and the performance was compared with standard attention.
Collapse
Affiliation(s)
- Suhail Haroon
- Bioinformatics Lab, Department of Computer Science, Cochin University of Science and Technology, Kerala 682022, India.
| | - Hafsath C A
- Bioinformatics Lab, Department of Computer Science, Cochin University of Science and Technology, Kerala 682022, India
| | - Jereesh A S
- Bioinformatics Lab, Department of Computer Science, Cochin University of Science and Technology, Kerala 682022, India.
| |
Collapse
|
98
|
Raza A, Chohan TA, Buabeid M, Arafa ESA, Chohan TA, Fatima B, Sultana K, Ullah MS, Murtaza G. Deep learning in drug discovery: a futuristic modality to materialize the large datasets for cheminformatics. J Biomol Struct Dyn 2023; 41:9177-9192. [PMID: 36305195 DOI: 10.1080/07391102.2022.2136244] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2022] [Accepted: 10/08/2022] [Indexed: 10/31/2022]
Abstract
Artificial intelligence (AI) development imitates the workings of the human brain to comprehend modern problems. The traditional approaches such as high throughput screening (HTS) and combinatorial chemistry are lengthy and expensive to the pharmaceutical industry as they can only handle a smaller dataset. Deep learning (DL) is a sophisticated AI method that uses a thorough comprehension of particular systems. The pharmaceutical industry is now adopting DL techniques to enhance the research and development process. Multi-oriented algorithms play a crucial role in the processing of QSAR analysis, de novo drug design, ADME evaluation, physicochemical analysis, preclinical development, followed by clinical trial data precision. In this study, we investigated the performance of several algorithms, including deep neural networks (DNN), convolutional neural networks (CNN) and multi-task learning (MTL), with the aim of generating high-quality, interpretable big and diverse databases for drug design and development. Studies have demonstrated that CNN, recurrent neural network and deep belief network are compatible, accurate and effective for the molecular description of pharmacodynamic properties. In Covid-19, existing pharmacological compounds has also been repurposed using DL models. In the absence of the Covid-19 vaccine, remdesivir and oseltamivir have been widely employed to treat severe SARS-CoV-2 infections. In conclusion, the results indicate the potential benefits of employing the DL strategies in the drug discovery process.Communicated by Ramaswamy H. Sarma.
Collapse
Affiliation(s)
- Ali Raza
- Department of pharmaceutical chemistry, Faculty of Pharmacy, The University of Lahore, Pakistan
- Institute of Molecular Biology and Biochemistry, The University of Lahore, Pakistan
| | - Talha Ali Chohan
- Institute of Molecular Biology and Biochemistry, The University of Lahore, Pakistan
- Institute of Pharmaceutical Science, UVAS, Lahore, Pakistan
| | - Manal Buabeid
- Department of Clinical Sciences, College of Pharmacy and Health Sciences, Ajman University, Ajman, United Arab Emirates
| | - El-Shaima A Arafa
- Department of Clinical Sciences, College of Pharmacy and Health Sciences, Ajman University, Ajman, United Arab Emirates
- Centre of Medical and Bio-Allied Health Sciences Research, Ajman University, Ajman, United Arab Emirates
| | | | - Batool Fatima
- Department of biochemistry, Bahauddin Zakariya University, Multan, Pakistan
| | - Kishwar Sultana
- Department of pharmaceutical chemistry, Faculty of Pharmacy, The University of Lahore, Pakistan
| | - Malik Saad Ullah
- Department of Pharmacy, Government College University, Faisalabad, Pakistan
| | - Ghulam Murtaza
- Department of Pharmacy, COMSATS University Islamabad, Lahore Campus, Pakistan
| |
Collapse
|
99
|
Ahmad B, Achek A, Farooq M, Choi S. Accelerated NLRP3 inflammasome-inhibitory peptide design using a recurrent neural network model and molecular dynamics simulations. Comput Struct Biotechnol J 2023; 21:4825-4835. [PMID: 37854633 PMCID: PMC10579963 DOI: 10.1016/j.csbj.2023.09.038] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2023] [Revised: 09/27/2023] [Accepted: 09/27/2023] [Indexed: 10/20/2023] Open
Abstract
Anomalous NLRP3 inflammasome responses have been linked to multiple health issues, including but not limited to atherosclerosis, diabetes, metabolic syndrome, cardiovascular disease, and neurodegenerative disease. Thus, targeting NLRP3 and modulating its associated immune response might be a promising strategy for developing new anti-inflammatory drugs. Herein, we report a computational method for de novo peptide design for targeting NLRP3 inflammasomes. The described method leverages a long-short-term memory (LSTM) network based on a recurrent neural network (RNN) to model a valuable latent space of molecules. The resulting classifiers are utilized to guide the selection of molecules generated by the model based on circular dichroism spectra and physicochemical features derived from high-throughput molecular dynamics simulations. Of the experimentally tested sequences, 60% of the peptides showed NLRP3-mediated inhibition of IL-1β and IL-18. One peptide displayed high potency against NLRP3-mediated IL-1β inhibition. However, NLRC4 and AIM2 inflammasome-mediated IL-1β secretion was uninterrupted by this peptide, demonstrating its selectivity toward the NLRP3 inflammasome. Overall, these results indicate that deep learning and molecular dynamics can accelerate the discovery of NLRP3 inhibitors with potent and selective activity.
Collapse
Affiliation(s)
- Bilal Ahmad
- Department of Molecular Science and Technology, Ajou University, Suwon 16499, South Korea
- S&K Therapeutics, Ajou University, Campus Plaza 418, Worldcup-ro 199, Yeongtong-gu, Suwon 16502, South Korea
| | - Asma Achek
- Department of Molecular Science and Technology, Ajou University, Suwon 16499, South Korea
- Technology Development Platform, Institut Pasteur Korea, Seongnam 13488, Soouth Korea
| | - Mariya Farooq
- Department of Molecular Science and Technology, Ajou University, Suwon 16499, South Korea
- S&K Therapeutics, Ajou University, Campus Plaza 418, Worldcup-ro 199, Yeongtong-gu, Suwon 16502, South Korea
| | - Sangdun Choi
- Department of Molecular Science and Technology, Ajou University, Suwon 16499, South Korea
- S&K Therapeutics, Ajou University, Campus Plaza 418, Worldcup-ro 199, Yeongtong-gu, Suwon 16502, South Korea
| |
Collapse
|
100
|
Arras P, Yoo HB, Pekar L, Clarke T, Friedrich L, Schröter C, Schanz J, Tonillo J, Siegmund V, Doerner A, Krah S, Guarnera E, Zielonka S, Evers A. AI/ML combined with next-generation sequencing of VHH immune repertoires enables the rapid identification of de novo humanized and sequence-optimized single domain antibodies: a prospective case study. Front Mol Biosci 2023; 10:1249247. [PMID: 37842638 PMCID: PMC10575757 DOI: 10.3389/fmolb.2023.1249247] [Citation(s) in RCA: 5] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2023] [Accepted: 08/31/2023] [Indexed: 10/17/2023] Open
Abstract
Introduction: In this study, we demonstrate the feasibility of yeast surface display (YSD) and nextgeneration sequencing (NGS) in combination with artificial intelligence and machine learning methods (AI/ML) for the identification of de novo humanized single domain antibodies (sdAbs) with favorable early developability profiles. Methods: The display library was derived from a novel approach, in which VHH-based CDR3 regions obtained from a llama (Lama glama), immunized against NKp46, were grafted onto a humanized VHH backbone library that was diversified in CDR1 and CDR2. Following NGS analysis of sequence pools from two rounds of fluorescence-activated cell sorting we focused on four sequence clusters based on NGS frequency and enrichment analysis as well as in silico developability assessment. For each cluster, long short-term memory (LSTM) based deep generative models were trained and used for the in silico sampling of new sequences. Sequences were subjected to sequence- and structure-based in silico developability assessment to select a set of less than 10 sequences per cluster for production. Results: As demonstrated by binding kinetics and early developability assessment, this procedure represents a general strategy for the rapid and efficient design of potent and automatically humanized sdAb hits from screening selections with favorable early developability profiles.
Collapse
Affiliation(s)
- Paul Arras
- Antibody Discovery and Protein Engineering, Merck Healthcare KGaA, Darmstadt, Germany
- Institute for Organic Chemistry and Biochemistry, Technical University of Darmstadt, Darmstadt, Germany
| | - Han Byul Yoo
- Antibody Discovery and Protein Engineering, Merck Healthcare KGaA, Darmstadt, Germany
| | - Lukas Pekar
- Antibody Discovery and Protein Engineering, Merck Healthcare KGaA, Darmstadt, Germany
| | - Thomas Clarke
- Bioinformatics, EMD Serono, Billerica, MA, United States
| | - Lukas Friedrich
- Computational Chemistry and Biologics, Merck Healthcare KGaA, Darmstadt, Germany
| | | | - Jennifer Schanz
- ADCs & Targeted NBE Therapeutics, Merck KGaA, Darmstadt, Germany
| | - Jason Tonillo
- ADCs & Targeted NBE Therapeutics, Merck KGaA, Darmstadt, Germany
| | - Vanessa Siegmund
- Early Protein Supply and Characterization, Merck Healthcare KGaA, Darmstadt, Germany
| | - Achim Doerner
- Antibody Discovery and Protein Engineering, Merck Healthcare KGaA, Darmstadt, Germany
| | - Simon Krah
- Antibody Discovery and Protein Engineering, Merck Healthcare KGaA, Darmstadt, Germany
| | - Enrico Guarnera
- Antibody Discovery and Protein Engineering, Merck Healthcare KGaA, Darmstadt, Germany
| | - Stefan Zielonka
- Antibody Discovery and Protein Engineering, Merck Healthcare KGaA, Darmstadt, Germany
- Institute for Organic Chemistry and Biochemistry, Technical University of Darmstadt, Darmstadt, Germany
| | - Andreas Evers
- Antibody Discovery and Protein Engineering, Merck Healthcare KGaA, Darmstadt, Germany
| |
Collapse
|